|
<?xml version="1.0" encoding="UTF-8" standalone="yes"?> |
|
<tmx version="1.4"> |
|
<header adminlang="en" creationdate="20200507T111552Z" creationtool="mALIGNa" creationtoolversion="2" datatype="plaintext" o-tmf="al" segtype="block" srclang="en"> |
|
<prop type="distributor">ELRC project</prop> |
|
<prop type="description">Acquisition of bilingual data (from multilingual websites), normalization, cleaning, deduplication and identification of parallel documents have been done by ILSP-FC tool. Multilingual embeddings -based approach was adopted for alignment of segments. Merging/filtering of segment pairs has also been applied.</prop> |
|
<prop type="l1">en</prop> |
|
<prop type="l2">mt</prop> |
|
<prop type="lengthInTUs">391</prop> |
|
<prop type="# of words in l1">6221</prop> |
|
<prop type="# of words in l2">5397</prop> |
|
<prop type="# of unique words in l1">1469</prop> |
|
<prop type="# of unique words in l2">1254</prop> |
|
</header> |
|
<body> |
|
<tu tuid="1"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 4 // 37 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 5 // 47 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="2"> |
|
<prop type="lengthRatio">1.170731707317073</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="3"> |
|
<prop type="lengthRatio">0.4857142857142857</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pubbliku ġenerali</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for the general public</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="4"> |
|
<prop type="lengthRatio">1.875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Issortja skont:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Sort by:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="5"> |
|
<prop type="lengthRatio">1.0555555555555556</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-awtomedikazzjoni bl-antibijotiċi mhijiex użu responsabbli tal-antibijotiċi</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Self-medication with antibiotics is not a responsible use of antibiotics</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="6"> |
|
<prop type="lengthRatio">0.9024390243902439</prop> |
|
<tuv xml:lang="en"> |
|
<seg>fornituri tal-kura tas-saħħa primarja</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for primary care prescribers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="7"> |
|
<prop type="lengthRatio">0.98</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Audience: prattikanti ġenerali</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Audience: general practitioners</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="8"> |
|
<prop type="lengthRatio">1.263157894736842</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>information material, toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="9"> |
|
<prop type="lengthRatio">1.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 3 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 3 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="10"> |
|
<prop type="lengthRatio">1.1685393258426966</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Fuljett tal-pazjent għat-tobba li joħorġu riċetti fis-settur tal-kura primarja li jistgħu jagħtu lill-pazjenti: jispjega x'inhi r-reżistenza antibijotika u għala huwa importanti l-użu xieraq tal-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>A patient leaflet for primary care prescribers to hand out to patients: it explains to patients what antibiotic resistance is and why appropriate use of antibiotics is important.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="11"> |
|
<prop type="lengthRatio">1.4242424242424243</prop> |
|
<tuv xml:lang="en"> |
|
<seg>JUM EWROPEW GĦALL-GĦARFIEN DWAR L-ANTIBIJOTIĊI</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>European Antibiotic Awareness Day</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="12"> |
|
<prop type="lengthRatio">0.42953020134228187</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, preżentazzjoni, materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Documenting indication, drug choice, dose, route of administration and duration of treatment in the patient chart leads to better use of antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="13"> |
|
<prop type="lengthRatio">1.1333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Type: materjal ta' informazzjoni</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: information material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="14"> |
|
<prop type="lengthRatio">2.3529411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 4 minn 4 // 40 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 4 of 5 // 50</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="15"> |
|
<prop type="lengthRatio">1.3636363636363635</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Evitaw profilassi antibijotika bla bżonn (eż.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>European Antibiotic Awareness Day</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="16"> |
|
<prop type="lengthRatio">0.7516778523489933</prop> |
|
<tuv xml:lang="en"> |
|
<seg>batterju, virus, jew parassita, bħall-parassita tal-malarja) li jirreżisti l-azzjoni tas-sustanza antimikrobika.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Documenting indication, drug choice, dose, route of administration and duration of treatment in the patient chart leads to better use of antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="17"> |
|
<prop type="lengthRatio">1.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 1 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 1 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="18"> |
|
<prop type="lengthRatio">1.2439024390243902</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Type: materjal ta' informazzjoni</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="19"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 2 // 13 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 3 // 23 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="20"> |
|
<prop type="lengthRatio">0.7</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Applika</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Media type</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="21"> |
|
<prop type="lengthRatio">1.5238095238095237</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Messaġġi ewlenin għall-ispeċjalisti tal-mard infettiv tal-isptar</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Poster for intensive care unit physicians:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="22"> |
|
<prop type="lengthRatio">1.08</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Aktar informazzjoni fuq: www.antibiotic.ecdc.europa.eu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>More information at: www.antibiotic.ecdc.europa.eu</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="23"> |
|
<prop type="lengthRatio">2.3529411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 3 minn 4 // 40 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 3 of 5 // 50</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="24"> |
|
<prop type="lengthRatio">1.2264150943396226</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Din hija protezzjoni effettiva kontra l-irjiħat jew l-influwenza?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Is this an effective protection against colds or flu?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="25"> |
|
<prop type="lengthRatio">1.7</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pubbliku ġenerali</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Media type</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="26"> |
|
<prop type="lengthRatio">0.625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Neither are antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="27"> |
|
<prop type="lengthRatio">1.2291666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, powster, materjal tat-toolkit -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>information material, poster, toolkit material -</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="28"> |
|
<prop type="lengthRatio">1.2222222222222223</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, materjal tat-toolkit, vidjo</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>information material, toolkit material, video</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="29"> |
|
<prop type="lengthRatio">1.2391304347826086</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, powster, materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>information material, poster, toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="30"> |
|
<prop type="lengthRatio">1.1724137931034482</prop> |
|
<tuv xml:lang="en"> |
|
<seg>jekk għandek 'il fuq minn 65 sena;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>if you are over 65 years old;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="31"> |
|
<prop type="lengthRatio">1.28</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni messaġġi ewlenin materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>information material key messages toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="32"> |
|
<prop type="lengthRatio">1.170731707317073</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Jekk tieħu l-antibijotiċi dawn mhux se jnaqqsulek is-severità tas-sintomi tiegħek u mhux se jgħinuk tħossok aħjar aktar malajr [10, 12, 15, 17].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Taking antibiotics will not reduce the severity of your symptoms and will not help you feel better faster [10, 12, 15, 17].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="33"> |
|
<prop type="lengthRatio">1.051948051948052</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-awtomedikazzjoni bl-antibijotiċi mhijiex użu responsabbli tal-antibijotiċi [8].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Self-medication with antibiotics is not a responsible use of antibiotics [8].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="34"> |
|
<prop type="lengthRatio">0.8873239436619719</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tul indikattiv ta' sintomi għal mard komuni tax-xitwa fl-adulti</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Indicative duration of symptoms for common winter illnesses in adults</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="35"> |
|
<prop type="lengthRatio">0.6138613861386139</prop> |
|
<tuv xml:lang="en"> |
|
<seg>bronkite kronika, enfisema, mard pulmonari ostruttiv kroniku);</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>if you have lung disease (e.g. chronic bronchitis, emphysema, chronic obstructive pulmonary disease);</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="36"> |
|
<prop type="lengthRatio">1.6923076923076923</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Infezzjoni fil-widnejn</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Ear infection</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="37"> |
|
<prop type="lengthRatio">1.1336633663366336</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Lista adattata minn ‘Ġenomika biex tiġi miġġielda r-reżistenza kontra l-antibijotiċi f'LRTI li tittieħed mill-komunità fl-Ewropa, proġett iffinanzjat mid-Direttorat Ġenerali tal-Kummissjoni Ewropea għar-Riċerka u l-Innovazzjoni.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>List adapted from ‘Genomics to combat resistance against antibiotics in community-acquired LRTI in Europe', a project funded by the European Commission's Directorate-General for Research and Innovation.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="38"> |
|
<prop type="lengthRatio">1.0126582278481013</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Bil-kelma "antibijotiċi", l-ECDC ifisser aġenti antibatteriċi jew antibatteriċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>With the word "antibiotics", ECDC means antibacterial agents or antibacterials.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="39"> |
|
<prop type="lengthRatio">1.1130952380952381</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-antibijotiċi huma effettivi biss kontra infezzjonijiet batteriċi u ma jistgħux jgħinuk tirkupra minn infezzjonijiet ikkawżati minn ‘viruses' bħar-riħ komuni jew l-influwenza [9-12, 14].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotics are only effective against bacterial infections and cannot help you recover from infections caused by viruses such as the common cold or the flu [9-12, 14].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="40"> |
|
<prop type="lengthRatio">1.2832618025751072</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Jekk tieħu l-antibijotiċi biex tiġġieled infezzjonijiet batteriċi ħfief, bħal rinosinusite, uġigħ fil-griżmejn, bronkite jew uġigħ fil-widnejn, ħafna drabi dan ikun bla bżonn [15-19] peress li, f'ħafna każijiet, is-sistema immuni tal-ġisem tiegħek hija kapaċi tindirizza dawn l-infezzjonijiet ħfief.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Taking antibiotics to fight mild bacterial infections, such as rhinosinusitis, sore throats, bronchitis or earaches, is often unnecessary [15-19] since, in most cases, your own immune system is able to deal with such mild infections.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="41"> |
|
<prop type="lengthRatio">1.2682926829268293</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Barra minn hekk, l-antibijotiċi jistgħu jikkawżaw diversi effetti sekondarji li mhuma xejn pjaċevoli bħal dijarea, dardir jew raxx fil-ġilda [9, 10, 13-15].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>In addition, antibiotics may cause several unpleasant side effects such as diarrhoea, nausea or skin rashes [9, 10, 13-15].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="42"> |
|
<prop type="lengthRatio">0.9166666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Infografika</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Infographics</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="43"> |
|
<prop type="lengthRatio">1.185</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-infografika tispjega l-proċess ta' reżistenza għall-antibijotiċi, ir-relazzjoni bejn il-konsum tal-antibijotiċi u r-reżistenza għall-antimikrobiċi, ix-xejra riċenti ta' reżistenza li qed tikber għal antibijotiċi tal-aħħar ġenerazzjoni.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Infographics explaining the process of antibiotic resistance, the relation between antibiotic consumption and antimicrobial resistance, the recent trend of growing resistance to last-line antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="44"> |
|
<prop type="lengthRatio">1.5238095238095237</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Skeda informattiva għall-esperti</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Factsheet for experts</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="45"> |
|
<prop type="lengthRatio">0.8296296296296296</prop> |
|
<tuv xml:lang="en"> |
|
<seg>batterju, virus, jew parassita, bħall-parassita tal-malarja) li jirreżisti l-azzjoni tas-sustanza antimikrobika.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antimicrobial resistance is the ability of a microorganism (e.g., a bacterium, a virus) to resist the action of an antimicrobial agent.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="46"> |
|
<prop type="lengthRatio">1.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 8 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 8 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="47"> |
|
<prop type="lengthRatio">1.3725490196078431</prop> |
|
<tuv xml:lang="en"> |
|
<seg>skeda informattiva, materjal ta' informazzjoni, materjal tat-toolkit -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>factsheet, information material, toolkit material -</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="48"> |
|
<prop type="lengthRatio">0.5833333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Applika</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Infographics</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="49"> |
|
<prop type="lengthRatio">1.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 6 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 6 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="50"> |
|
<prop type="lengthRatio">1.0684931506849316</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tevitaw testijiet dijanjostiċi u kulturi f'pazjenti mhux sintomatiċi [56,111].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Avoiding diagnostic tests and cultures in asymptomatic patients [56,111].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="51"> |
|
<prop type="lengthRatio">1.2647058823529411</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• tbiddlu għal terapija antibijotika orali.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>switch to oral antibiotic therapy.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="52"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• antibijotiċi topiċi; u</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>topical antibiotics; and</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="53"> |
|
<prop type="lengthRatio">1.135135135135135</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ippromwovu l-programmi ta' tilqim għar-residenti u l-persunal [kunsens tal-esperti].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Promote vaccination programmes for residents and staff [expert consensus].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="54"> |
|
<prop type="lengthRatio">1.1388888888888888</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Organizzaw avvenimenti u kampanji edukattivi li jipprovdu informazzjoni lir-residenti dwar l-użu prudenti tal-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Organise educational events and campaigns that provide residents with information on prudent antibiotic use.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="55"> |
|
<prop type="lengthRatio">1.1446280991735538</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ħudu sehem b'mod regolari f'korsijiet tat-taħriġ u f'laqgħat li jappoġġjaw l-implimentazzjoni fl-isptar ta': a) użu antibijotiku prudenti, b) linji gwida dwar l-antibijotiċi lokali, ibbażati fuq l-evidenza, u c) miżuri ta' prevenzjoni u ta' kontroll tal-infezzjonijiet [52,53].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Regularly participate in training courses and in meetings that support the implementation in the hospital of: a) prudent antibiotic use, b) evidence-based, local antibiotic guidelines, and c) infection prevention and control measures [52,53].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="56"> |
|
<prop type="lengthRatio">1.1910828025477707</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Iddokumentaw l-indikazzjoni ta' trattament antibijotiku, l-għażla tal-mediċina, id-doża, ir-rotta tal-amministrazzjoni u t-tul ta' żmien tat-trattament fiċ-ċart tal-pazjent [31,42,70,71].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>13. Document the indication of antibiotic treatment, drug choice, dose, route of administration and duration of treatment in the patient chart [31,42,70,71].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="57"> |
|
<prop type="lengthRatio">0.6222222222222222</prop> |
|
<tuv xml:lang="en"> |
|
<seg>profilassi tal-infezzjoni tal-apparat tal-awrina) [111].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Avoid unnecessary antibiotic prophylaxis (e.g. urinary tract infection prophylaxis) [111].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="58"> |
|
<prop type="lengthRatio">0.7287581699346405</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pulmonite, infezzjonijiet fil-parti ta' fuq tal-apparat respiratorju, infezzjonijiet tal-ġilda u tat-tessuti r-rotob u l-infezzjonijiet tal-apparat tal-awrina) u tqis id-dejta tas-suxxettibbiltà antimikrobjali lokali [109].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Using clinical pathways and evidence-based guidelines for diagnosing, treating and managing the most common infections (e.g. pneumonia, upper respiratory tract infections, skin and soft tissue infections, and urinary tract infections), and taking into account local antimicrobial susceptibility data [109].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="59"> |
|
<prop type="lengthRatio">1.0175438596491229</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tibda t-trattament antibijotiku biss jekk hemm evidenza ta' infezzjoni batterjali u tittrattawx kolonizzazzjoni[31].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Only start antibiotic treatment if there is evidence of a bacterial infection, and do not treat colonisation [31].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="60"> |
|
<prop type="lengthRatio">1.2608695652173914</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• il-propilassi antibijotika;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>antibiotic prophylaxis;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="61"> |
|
<prop type="lengthRatio">0.9866666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Livelli dejjem jiżdiedu ta' reżistenza antibijotika jheddu l-effikaċja tal-antibijotiċi fil-preżent u fil-futur: il-komunikazzjoni effettiva mal-pazjenti hija essenzjali biex tiġi indirizzata din il-problema dejjem tikber.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>A model for a patient dialogue on the basis of available evidence provides guidance and support for primary care prescribers who encounter patient pressure for antibiotics, and promotes appropriate antibiotic use by patients.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="62"> |
|
<prop type="lengthRatio">0.8409090909090909</prop> |
|
<tuv xml:lang="en"> |
|
<seg>fornituri tal-kura tas-saħħa primarja</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Template letter for primary care prescribers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="63"> |
|
<prop type="lengthRatio">1.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 2 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 2 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="64"> |
|
<prop type="lengthRatio">1.4285714285714286</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Audience: dawk li jippreskrivu l-mediċina fl-isptar</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Audience: hospital prescribers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="65"> |
|
<prop type="lengthRatio">1.7</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pubbliku ġenerali</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Factsheets</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="66"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 2 // 17 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 2 // 19 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="67"> |
|
<prop type="lengthRatio">1.0434782608695652</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>information material, poster, toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="68"> |
|
<prop type="lengthRatio">0.9705882352941176</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ittra mudell għall-maniġment tal-isptar, li tippreżenta l-kampanja tal-Jum Ewropew għall-Għarfien dwar l-Antibijotiċi u ssejjaħ għal appoġġ fl-implimentazzjoni ta' strateġiji multisettorjali għall-amministrazzjoni tal-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The poster contains a key message that is deemed relevant overall for the hospital or the healthcare setting, followed by a set of actions that the hospital prescriber can/should/must implement to ensure that antibiotics remain effective.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="69"> |
|
<prop type="lengthRatio">2.3529411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 6 // 53 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 7 // 65</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="70"> |
|
<prop type="lengthRatio">2.142857142857143</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Issortja skont:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Poster:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="71"> |
|
<prop type="lengthRatio">1.1886792452830188</prop> |
|
<tuv xml:lang="en"> |
|
<seg>infografika, materjal ta' informazzjoni, materjal tat-toolkit -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>infographic, information material, toolkit material -</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="72"> |
|
<prop type="lengthRatio">0.7368421052631579</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Lanqas mhuma l-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>How does antibiotic resistance spread?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="73"> |
|
<prop type="lengthRatio">1.4042553191489362</prop> |
|
<tuv xml:lang="en"> |
|
<seg>skeda informattiva materjal ta' informazzjoni materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>factsheet information material toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="74"> |
|
<prop type="lengthRatio">0.5097402597402597</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Skeda informattiva dwar ir-reżistenza antibijotika fil-kura primarja tipprovdi lit-tobba li joħorġu riċetti b'dejta nazzjonali u tal-UE dwar l-aħħar xejriet.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Factsheet provides the latest available scientific evidence about antibiotic resistance that is relevant to hospitals: e.g. antibiotic resistance is increasing overall, bacteria that are resistant to multiple group of antibiotics is of particular concern, and antibiotic stewardship programmes are effective.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="75"> |
|
<prop type="lengthRatio">1.0419580419580419</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Wara l-adozzjoni tar-Rakkomandazzjoni tal-Kunsill tal-Unjoni Ewropea (UE) dwar l-użu prudenti ta' aġenti antimikrobjali f'Novembru 2001, li ddikjarat li l-Istati Membri tal-UE għandhom jinfurmaw lill-pubbliku ġenerali dwar l-importanza tal-użu prudenti ta' aġenti antimikrobjali u dwar is-suċċess ta' xi kampanji nazzjonali, bħall-Belġju u Franza, iċ-Ċentru Ewropew għall-Prevenzjoni u l-Kontroll tal-Mard (ECDC) fl-2008 iddeċieda li jistabbilixxi l-Jum Ewropew għall-Għarfien dwar l-Antibijotiċi (EEAD) fit-18 ta' Novembru bħala pjattaforma biex tagħti appoġġ lil kampanji nazzjonali fir-reġjun.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Following adoption of the European Union (EU) Council Recommendation on the prudent use of antimicrobial agents in human medicine in November 2001, which stated that EU Member States should inform the general public of the importance of prudent use of antimicrobial agents and the success of some national campaigns, such as Belgium and France, the European Centre for Disease Prevention and Control (ECDC) decided in 2008 to establish the European Antibiotic Awareness Day (EAAD) on 18 November as a platform for providing support to national campaigns across the region.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="76"> |
|
<prop type="lengthRatio">1.2666666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Finalment, fit-18 ta' Novembru ta' kull sena, l-ECDC jikkoordina l-Jum Ewropew għall-Għarfien dwar l-Antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Finally, on 18 November each year, ECDC coordinates the European Antibiotic Awareness Day.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="77"> |
|
<prop type="lengthRatio">0.6440129449838188</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-oqsma ewlenin ta' ħidma tal-ECDC jinkludu s-sorveljanza, l-intelliġenza epidemika, l-iżvilupp ta' gwida bbażata fuq l-evidenza u reviżjonijiet sistematiċi, taħriġ, appoġġ lill-Istati Membri tal-UE.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Activities related to this topic at ECDC, take place under the Antimicrobial Resistance and Healthcare-associated Infections programme . ECDC's main areas of work include surveillance, epidemic intelligence, developing evidence-based guidance and systematic reviews, training, support to the EU Member States.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="78"> |
|
<prop type="lengthRatio">1.114864864864865</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mill-2015, l-Organizzazzjoni Dinjija tas-Saħħa tmexxi l-Ġimgħa Dinjija għall-Għarfien dwar l-Antibijotiċi , kampanja globali li sseħħ fil-ġimgħa tat-18 ta' Novembru.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Since 2015, the World Health Organization leads the World Antibiotic Awareness Week , a global campaign taking place on the week of the 18 November.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="79"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tevita profilassi antibijotika bla bżonn [31,73].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Avoid unnecessary antibiotic prophylaxis [31,73].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="80"> |
|
<prop type="lengthRatio">1.625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Messaġġi ewlenin rilevanti għall-preskriventi kollha</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for all prescribers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="81"> |
|
<prop type="lengthRatio">1.165289256198347</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tieħu sehem b'mod regolari f'korsijiet tat-taħriġ u f'laqgħat li jappoġġjaw l-implimentazzjoni fl-isptar ta': a) użu prudenti tal-antibijotiċi, b) linji gwida dwar l-antibijotiċi lokali, ibbażati fuq l-evidenza, u c) miżuri ta' prevenzjoni u ta' kontroll tal-infezzjonijiet [52,53].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Regularly participate in training courses and in meetings that support the implementation in the hospital of: a) prudent antibiotic use, b) evidence-based, local antibiotic guidelines, and c) infection prevention and control measures [52,53].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="82"> |
|
<prop type="lengthRatio">0.9705882352941176</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-pazjent għandu infezzjoni li se tirrispondi għall-antibijotiċi?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Does the patient have an infection that will respond to antibiotics?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="83"> |
|
<prop type="lengthRatio">1.196078431372549</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tiddokumenta l-indikazzjoni ta' kura b'antibijotiċi, l-għażla tal-mediċina, id-doża, ir-rotta tal-amministrazzjoni u t-tul ta' żmien tat-trattament fiċ-ċart tal-pazjent [31,42,70,71].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Document the indication of antibiotic treatment, drug choice, dose, route of administration and duration of treatment in the patient chart [31,42,70,71].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="84"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• Tfittex gwida u parir minn kollega superjuri jew membru tat-tim tal-kontroll tal-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Seek guidance and advice from a senior colleague or a member of the antibiotic stewardship team.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="85"> |
|
<prop type="lengthRatio">1.0625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tiżgura li l-kulturi jittieħdu u jintbagħtu kif xieraq fil-laboratorju tal-mikrobijoloġija, qabel ma tibda l-antibijotiċi [31,42,70,71].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Ensure that cultures are appropriately taken and send to the microbiology laboratory, before starting antibiotics [31,42,70,71].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="86"> |
|
<prop type="lengthRatio">1.1363636363636365</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ibqa' konxju tal-mudelli tar-reżistenza għall-antibijotiċi lokali fid-dipartiment tiegħek, l-isptar tiegħek u fil-komunità [31] [kunsens tal-esperti].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remain aware of local antibiotic resistance patterns in your department, your hospital and in the community [31] [expert consensus].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="87"> |
|
<prop type="lengthRatio">1.1920529801324504</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Twieġeb il-mistoqsijiet ewlenin li ġejjin meta tivvaluta mill-ġdid it-terapija antibijotika wara 48-72 siegħa (jew hekk kif ir-riżultati mikrobijoloġiċi jsiru disponibbli) [42,70]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Answer the following key questions when reassessing antibiotic therapy after 48-72 hours (or as soon as microbiological results are available) [42,70]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="88"> |
|
<prop type="lengthRatio">2.3529411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 5 minn 6 // 53 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 5 of 7 // 65</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="89"> |
|
<prop type="lengthRatio">0.9666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Audience: professjonisti fl-isptarijiet</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Audience: healthcare workers in hospitals</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="90"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 2 // 13 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 3 // 25 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="91"> |
|
<prop type="lengthRatio">1.5365853658536586</prop> |
|
<tuv xml:lang="en"> |
|
<seg>infografika, materjal ta' informazzjoni, materjal tat-toolkit -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="92"> |
|
<prop type="lengthRatio">0.8571428571428571</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pajjiż</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Country</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="93"> |
|
<prop type="lengthRatio">2.4375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 6 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 5</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="94"> |
|
<prop type="lengthRatio">1.1521739130434783</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Type: toolkit għall-komunikazzjoni</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: communication toolkit</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="95"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>toolkit għall-komunikazzjoni</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>communication toolkit</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="96"> |
|
<prop type="lengthRatio">1.0273972602739727</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It-"toolkit" fiha materjali mudelli u messaġġi ewlenin li jiffukaw fuq l-awtomedikazzjoni bl-antibijotiċi, ideat għal attivitajiet ta' sensibilizzazzjoni, u tattiċi suġġeriti biex il-messaġġi jingħaddu lill-pubbliku ġenerali.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The toolkit contains template materials and key messages focusing on self-medication with antibiotics, ideas for awareness raising activities, and suggested tactics for getting the messages across to the general public.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="97"> |
|
<prop type="lengthRatio">2.4375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 5 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 5</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="98"> |
|
<prop type="lengthRatio">0.5384615384615384</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Applika</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="99"> |
|
<prop type="lengthRatio">1.0740740740740742</prop> |
|
<tuv xml:lang="en"> |
|
<seg>X'inhu "kunsens tal-esperti"?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>What is "expert consensus"?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="100"> |
|
<prop type="lengthRatio">1.0403022670025188</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ikopru għadd ta' professjonisti li jaħdmu fi sptarijiet u ambjenti oħrajn tal-kura tas-saħħa: maniġers/amministraturi, speċjalisti tal-mard infettiv, prevenzjoni tal-infezzjonijiet u professjonisti tal-kontroll, preskriventi, tobba subalterni u studenti, spiżjara, infermiera, mikrobijoloġisti kliniċi u professjonisti f'dipartimenti tal-emerġenza, fl-unitajiet tal-kura intensiva u faċilitajiet tal-kura fit-tul.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Cover a number of professionals working at hospitals and other healthcare settings: managers/administrators, infectious disease specialists, infection prevention and control professionals, epidemiologists, prescribers, junior doctors and students, pharmacists, nurses, clinical microbiologists, and professionals in emergency departments, in intensive care units, and in long-term care facilities.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="101"> |
|
<prop type="lengthRatio">1.0777027027027026</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Meta, f'dan id-dokument, referenza għal messaġġ hija indikata bħala "kunsens tal-esperti", l-ECDC jirreferi għall-ftehim milħuq fil-proċess imsemmi tat-teħid tad-deċiżjonijiet, inkluż il-ftehim intern tal-esperti tal-ECDC u l-opinjoni tal-membri EAAD TAC u konsultazzjoni mal-esperti esterni u l-partijiet ikkonċernati.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>When, in this document, a reference to a message is indicated as "expert consensus", ECDC is referring to the agreement reached in the outlined decision-making process, including ECDC experts' internal agreement, EAAD TAC members' opinion, and consultation with external experts and stakeholders.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="102"> |
|
<prop type="lengthRatio">1.2066115702479339</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Kull sena madwar l-Ewropa, l-EAAD huwa mmarkat permezz ta' kampanji nazzjonali dwar l-użu prudenti tal-antibijotiċi fit-18 ta' Novembru jew viċin.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Each year across Europe, EAAD is marked by national campaigns on the prudent use of antibiotics on or around 18 November.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="103"> |
|
<prop type="lengthRatio">1.2941176470588236</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Audience: fornituri tal-kura tas-saħħa primarja</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Audience: primary care providers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="104"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 3 minn 4 // 37 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 3 of 5 // 47 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="105"> |
|
<prop type="lengthRatio">1.2826086956521738</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, powster, materjal tat-toolkit -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>information material, poster, toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="106"> |
|
<prop type="lengthRatio">1.4</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Applika</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Apply</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="107"> |
|
<prop type="lengthRatio">1.125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Type: stejjer ta' pazjenti</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: patient stories</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="108"> |
|
<prop type="lengthRatio">2.4375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 4 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 5</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="109"> |
|
<prop type="lengthRatio">1.0802139037433156</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-batterju li ġie iżolat mil-fluss tad-demm ta' Mohammed kien reżistenti għal ħafna antibijotiċi, inkluż antibijotiċi tal-aħħar sors - klassi ta' antibijotiċi tal-aħħar ġenerazzjoni msejħa karbapenems.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The bacterium that was isolated from Mohammed's bloodstream was resistant to many antibiotics, including the last-source antibiotics - a class of last-line antibiotics called carbapenems.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="110"> |
|
<prop type="lengthRatio">0.9032258064516129</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paolo marad b'infezzjoni urinarja serja b'E.coli reżistenti għal ħafna antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Paolo fell ill with a serious urinary infection with an E.coli resistant to many antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="111"> |
|
<prop type="lengthRatio">0.7894736842105263</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Issortja skont:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>ECDC patient story:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="112"> |
|
<prop type="lengthRatio">1.3515625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Lill-Karin, in-Norveġja, ġiet infettata b'batterji reżistenti għal ħafna antibijotiċi wara inċident u perjodu ta' kura ġo sptar waqt li kienet fuq btala barra minn pajjiżha.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Lill-Karin, Norway, caught bacteria resistant to many antibiotics after an accident and a hospitay stay while on holiday abroad.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="113"> |
|
<prop type="lengthRatio">1.25</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Lill-Karin</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Mohammed</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="114"> |
|
<prop type="lengthRatio">2.3529411764705883</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 4 // 40 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 5 // 50</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="115"> |
|
<prop type="lengthRatio">1.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 5 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 4 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="116"> |
|
<prop type="lengthRatio">1.1357466063348416</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It-"toolkit" fiha materjali mudelli u messaġġi ewlenin għal professjonisti tas-saħħa, ideat għal attivitajiet ta' sensibilizzazzjoni, u tattiċi suġġeriti biex il-messaġġi jingħaddu kemm lil fornituri tal-kura tas-saħħa primarja kif ukoll lil pazjenti.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The toolkit contains template materials and key messages for health professionals, ideas for awareness raising activities, and suggested tactics for getting the messages across to both primary care providers and patients.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="117"> |
|
<prop type="lengthRatio">1.1458333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Audience: organizzaturi ta' kampanji</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Audience: campaign organisers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="118"> |
|
<prop type="lengthRatio">1.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 9 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 8 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="119"> |
|
<prop type="lengthRatio">1.2727272727272727</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 11 // 108 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 30 // 291 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="120"> |
|
<prop type="lengthRatio">0.9523809523809523</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>communication toolkit</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="121"> |
|
<prop type="lengthRatio">1.257462686567164</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ittri għall-awtoritajiet nazzjonali tas-saħħa pubblika se jintbagħtu lil spiżjara u lil dawk li jippreskrivu l-kura tas-saħħa primarja biex jintroduċu l-Jum Ewropew għall-Għarfien dwar l-Antibjotiċi (EEAD), biex jippromwovu l-użu xieraq tal-antibijotiċi u biex jinfurmaw lill-pazjenti dwar ir-riskji tal-awtomedikazzjoni bl-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Letters for national public health authorities to send to pharmacists and primary care prescribers to introduce European Antibiotic Awareness Day (EAAD), to promote appropriate use of antibiotics and inform patients about the risks of self-medication with antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="122"> |
|
<prop type="lengthRatio">1.2</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ittri f'forma ta' ‘template' għall-ispiżjara u t-tobba tal-kura primarja</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Template letters to pharmacists and primary care prescribers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="123"> |
|
<prop type="lengthRatio">1.511111111111111</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-ECDC jaħdem mill-qrib mal-Kummissjoni Ewropea u ma' aġenziji oħrajn tal-UE, partijiet interessati kif ukoll ma' organizzazzjonijiet biex imexxu kampanji ta' għarfien dwar l-użu prudenti tal-antibijotiċi</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antimicrobial resistance is the ability of a microorganism (e.g., a bacterium, a virus) to resist the action of an antimicrobial agent.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="124"> |
|
<prop type="lengthRatio">1.14</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Staphylococcus aureus reżistenti għall-metiċillina (MRSA)</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Methicillin-resistant Staphylococcus aureus (MRSA)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="125"> |
|
<prop type="lengthRatio">1.127659574468085</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Antifungali (attivi kontra l-infezzjonijiet fungali),</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antifungals (active against fungal infections),</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="126"> |
|
<prop type="lengthRatio">1.21656050955414</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Sitt Stati Membri (jiġifieri Franza, il-Belġju, is-Slovakkja, ir-Repubblika Ċeka, is-Slovenja u l-Iżvezja) dan l-aħħar irrappurtaw tendenzi ta' tnaqqis fl-użu ta' antibijotiċi fl-outpatients;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Six Member States (i.e. France, Belgium, Slovakia, Czech Republic, Slovenia and Sweden) recently reported decreasing trends in antibiotic use in outpatients;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="127"> |
|
<prop type="lengthRatio">1.0114942528735633</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mikrorganiżmi - li jissejħu wkoll mikrobi - jinkludu batterji, virus, fungi u parassiti.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Microorganisms - also called microbes - include bacteria, viruses, fungi and parasites.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="128"> |
|
<prop type="lengthRatio">1.018181818181818</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Iż-żewġ kawżi maġġuri tar-reżistenza antimikrobika huma:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The two major drivers for antimicrobial resistance are:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="129"> |
|
<prop type="lengthRatio">1.0258064516129033</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Enterobacteriaceae li jipproduċu beta-lattamażi ta' spettru wiesa' (ESBL) (eżempji ta' Enterobacteriaceae komuni huma Escherichia coli u Klebsiella pneumoniae)</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (examples of common Enterobacteriaceae are Escherichia coli and Klebsiella pneumoniae)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="130"> |
|
<prop type="lengthRatio">0.7698412698412699</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Salmonella u Campylobacter huma assoċjati mal-konsum ta' ikel kontaminat u jikkawżaw id-dijarrea;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Certain bacteria, e.g. Salmonella and Campylobacter are associated with consumption of contaminated foods and cause diarrhoea;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="131"> |
|
<prop type="lengthRatio">1.1891891891891893</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Stimi preliminari tal-għadd ta' mwiet attribwibbli direttament għal infezzjonijiet li ttieħdu fl-isptarijiet minħabba l-batterji l-aktar komuni reżistenti għal aktar minn mediċina waħda huma ta' 1/3 sa 1/2 ta' dak tal-infezzjonijiet totali li ttieħdu fl-isptarijiet (ara hawn taħt) (ECDC, dejta preliminari).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Preliminary estimates of the number of deaths directly attributable to hospital-acquired infections due to the most common major multidrug-resistant bacteria are 1/3 to 1/2 of that for hospital-acquired infections overall (see below) (ECDC, preliminary data).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="132"> |
|
<prop type="lengthRatio">1.1225806451612903</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Infezzjonijiet nosokomjali u r-reżistenza antimikrobika huma żewġ aspetti speċjali relatati mas-saħħa elenkati fl-Anness 1 tad-Deċiżjoni tal-Kummissjoni 2000/96/KE tat-22 ta' Diċembru 1999 dwar il-mard li jittieħed li għandu jkun kopert progressivament min-netwerk tal-Komunità skont id-Deċiżjoni Nru 2119/98/KE tal-Parlament Ewropew u tal-Kunsill.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Nosocomial infections and antimicrobial resistance are two special health issues listed in Annex 1 of Commission Decision 2000/96/EC of 22 December 1999 on the communicable diseases to be progressively covered by the Community network under Decision No 2119/98/EC of the European Parliament and of the Council.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="133"> |
|
<prop type="lengthRatio">0.5176470588235295</prop> |
|
<tuv xml:lang="en"> |
|
<seg>infezzjonijiet tal-influwenza, HIV, herpes),</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antivirals (active against viral infections, e.g. influenza, HIV, herpes infections),</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="134"> |
|
<prop type="lengthRatio">1.1571428571428573</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ir-Rapport Annwali 2007 tal-EARSS, kif ukoll dejta nazzjonali, indikaw tendenzi ta' tnaqqis fir-reżistenza fi Streptococcus pneumoniae, batterji li huma responsabbli b'mod komuni għall-infezzjonijiet fl-outpatients, b'mod partikolari fit-tfal;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The EARSS Annual Report 2007, as well as national data, indicated decreasing resistance trends in Streptococcus pneumoniae, a bacteria commonly responsible for infections in outpatients, in particular children;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="135"> |
|
<prop type="lengthRatio">1.0813953488372092</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Prekawzjonijiet iġjeniċi għall-kontroll ta' trasmissjoni ta' mikrorganiżmi reżistenti għall-antimikrobiċi (kontroll tal-infezzjoni), inklużi l-iġjene tal-idejn, skrining, iżolament, eċċ.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Hygienic precautions for the control of cross-transmission of antimicrobial-resistant microorganisms (infection control), including hand hygiene, screening, isolation, etc.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="136"> |
|
<prop type="lengthRatio">1.2425742574257426</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mingħajr antibijotiċi effikaċi, il-kura intensiva, it-trapjant tal-organi, il-kemjoterapija kontra l-kanċer, il-kura ta' trabi prematuri, jew saħansitra l-proċeduri kirurġiċi komuni, bħas-sostituzzjoni tal-ġenbejn jew tal-irkoppa, ma jkunux possibbli.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Without effective antibiotics, intensive care, organ transplants, cancer chemotherapy, care of preterm babies, or even common surgical procedures, such as hip or knee replacement, would not be possible.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="137"> |
|
<prop type="lengthRatio">2.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Lill-Karin</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Paolo</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="138"> |
|
<prop type="lengthRatio">1.105263157894737</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ingħaqad mal-kampanja</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>ECDC patient story:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="139"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 2 minn 2 // 14 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 2 of 2 // 16 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="140"> |
|
<prop type="lengthRatio">1.25</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, materjal tat-toolkit, vidjo</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: teabepakme materjal</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="141"> |
|
<prop type="lengthRatio">1.1296296296296295</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Jekk għandek riħ jew influwenza, ħu ħsieb, mhux antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>If you have a cold or flu, take care, not antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="142"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 2 // 15 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 2 // 17 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="143"> |
|
<prop type="lengthRatio">1.2203389830508475</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paolo għandu 55 sena u huwa Professur fl-Università ta' Ruma, fl-Italja.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Paolo is a 55 year old University Professor in Rome, Italy.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="144"> |
|
<prop type="lengthRatio">1.3181818181818181</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Kummentarju: noti dwar il-każ</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Commentary: case notes</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="145"> |
|
<prop type="lengthRatio">0.9659090909090909</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Għaldaqstant, hemm bżonn li wieħed jara tabib u li jsirulu testijiet mikrobijoloġiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>It is therefore necessary to see a doctor and to have microbiological testing performed.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="146"> |
|
<prop type="lengthRatio">1.0921052631578947</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Barra minn hekk, kien allerġiku għal wieħed minnhom, trimethoprim-sulfamethoxazole.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Additionally, he was allergic to one of them, trimethoprim-sulfamethoxazole.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="147"> |
|
<prop type="lengthRatio">1.0985915492957747</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-kultura wriet li kien infettat b'batterju msejjaħ Escherichia coli (E. coli), li pproduċa lactamase beta bi spettru estiż (ESBL - extended-spectrum beta-lactamase) u li kien reżistenti għal bosta antibijotiċi, inkluż ciprofloxacin.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The culture showed that he was infected with a bacterium called Escherichia coli (E. coli), which produced an extended-spectrum beta-lactamase (ESBL) and was resistant to many antibiotics, including ciprofloxacin.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="148"> |
|
<prop type="lengthRatio">0.9888268156424581</prop> |
|
<tuv xml:lang="en"> |
|
<seg>ESBLs huma enzimi li jagħmlu l-batterji, spiss E. coli u Klebsiella pneumoniae, reżistenti għal ħafna mill-antibijotiċi β-lactam, inklużi peniċillini, ċefalosporini u aztreonam.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>ESBLs are enzymes that make bacteria, most commonly E. coli and Klebsiella pneumoniae, resistant to most β-lactam antibiotics, including penicillins, cephalosporins and aztreonam.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="149"> |
|
<prop type="lengthRatio">1.3691275167785235</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-ECDC jaħdem mill-qrib mal-Kummissjoni Ewropea u ma' aġenziji oħrajn tal-UE, partijiet interessati kif ukoll ma' organizzazzjonijiet biex imexxu kampanji ta' għarfien dwar l-użu prudenti tal-antibijotiċi</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Documenting indication, drug choice, dose, route of administration and duration of treatment in the patient chart leads to better use of antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="150"> |
|
<prop type="lengthRatio">1.5609756097560976</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal ta' informazzjoni, preżentazzjoni, materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="151"> |
|
<prop type="lengthRatio">1.5925925925925926</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Preżentazzjoni li tista' tintuża waqt is-sessjonijiet ta' taħriġ fl-isptar li tagħti dettalji dwar il-kwistjonijiet ewlenin relatati mar-reżistenza antibijotika u l-modi li bihom jista' jittejjeb l-użu antibijotiku.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antimicrobial resistance is the ability of a microorganism (e.g., a bacterium, a virus) to resist the action of an antimicrobial agent.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="152"> |
|
<prop type="lengthRatio">1.1875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>e) Li tipprovdu informazzjoni dwar it-trattamenti lill-pazjenti u l-familji;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>e) Providing information on treatments to patients and families;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="153"> |
|
<prop type="lengthRatio">1.0505050505050506</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) Ir-rapportr ta' effetti ħżiena tat-terapija antibijotika lit-tobba u kumitati tar-reviżjoni adegwati;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Reporting adverse effects of antibiotic therapy to physicians and appropriate review committees;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="154"> |
|
<prop type="lengthRatio">1.076470588235294</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tiżguraw li l-pazjenti (u l-familji tagħhom) jifhmu r-raġuni għat-terapija antibijotika u l-punti ewlenin relatati mal-użu tal-antibijotiku, inkluż biex [31,69] [kunsens tal-esperti]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Ensure that patients (and their families) understand the reason for antibiotic therapy, and key points related to antibiotic use, including to [31,69] [expert consensus]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="155"> |
|
<prop type="lengthRatio">1.224</prop> |
|
<tuv xml:lang="en"> |
|
<seg>d) Il-faċilitazzjoni tal-komunikazzjoni bejn it-tobba, l-ispiżerija, il-laboratorju u l-pjanifikaturi tar-rilaxx mill-isptar, il-konsulenti u l-pazjenti;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>d) Facilitating communication between physicians, the pharmacy, the laboratory, discharge planners, consultants and patients;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="156"> |
|
<prop type="lengthRatio">1.4786324786324787</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ħeġġu lill-preskriventi biex jiddokumentaw minnufih id-deċiżjoni ta' reviżjoni tagħhom għall-pazjenti kollha li jkunu qed jieħdu l-antibijotiku wara 48-72 siegħa [31,42,69].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Prompt prescribers to document their reviewing decision for all patients on antibiotics after 48-72 hours [31,42,69].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="157"> |
|
<prop type="lengthRatio">0.9801980198019802</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ittejbu l-prattiki tal-kontroll tal-antibijotiċi b'kollaborazzjoni mat-tobba u l-ispiżjara [96,97].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>3. Improve antibiotic administration practices in collaboration with doctors and pharmacists [96,97].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="158"> |
|
<prop type="lengthRatio">1.088</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tiżguraw li l-kulturi jittieħdu u jintbagħtu kif adegwat fil-laboratorju tal-mikrobijoloġija, qabel ma jibdew l-antibijotiċi [31,42,70].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Ensure that cultures are appropriately taken and send to the microbiology laboratory, before starting antibiotics [31,42,70].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="159"> |
|
<prop type="lengthRatio">0.4878048780487805</prop> |
|
<tuv xml:lang="en"> |
|
<seg>materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="160"> |
|
<prop type="lengthRatio">1.5</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Skeda informattiva għall-pubbliku ġenerali</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Factsheet for general public</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="161"> |
|
<prop type="lengthRatio">1.0217391304347827</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Jappartjeni għall-familja ta' batterji msejħa Enterobacteriacae (bi Klebsiella, Enterobacter).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>It belongs to a family of bacteria called Enterobacteriacae (with Klebsiella, Enterobacter).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="162"> |
|
<prop type="lengthRatio">0.9230769230769231</prop> |
|
<tuv xml:lang="en"> |
|
<seg>X'inhu MRSA?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>What is MRSA?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="163"> |
|
<prop type="lengthRatio">1.0961538461538463</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Staphylococcus aureus huwa batterju komuni, preżenti fuq il-ġilda u l-mukoża f'20% sa 30% ta' persuni f'saħħithom.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Staphylococcus aureus is a common bacterium, present on skin and mucosa in 20% to 30% of healthy people.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="164"> |
|
<prop type="lengthRatio">1.2467741935483871</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-pazjenti fl-isptarijiet huma f'riskju ta' infezzjonijiet li mhumiex relatati mar-raġuni li għaliha jkunu ddaħħlu l-isptar, inkluż infezzjonijiet fid-demm u fil-post tal-operazzjoni bħal MRSA (ikkawżata minn Staphylococcus aureus reżistenti għall-metiċillina (methicillin), antibijotiku li jirrappreżenta lil dawk li normalment huma effikaċi kontra Staphylococcus aureus), infezzjonijiet fid-demm ikkawżati minn Enterobacteriaceae li jipproduċu ESBL (beta-lattamażi ta' spettru wiesa', enzimi li kapaċi jeqirdu ċerti antibijotiċi), infezzjonijiet fil-valvoli tal-qalb ikkawżati minn Enteroccocci reżistenti għall-vankomiċina (vancomycin), u infezzjonijiet fil-post tal-operazzjoni kirurġika u tal-ġrieħi kkawżati minn Acinetobacter baumannii reżistenti għall-carbapenems.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Patients in hospitals are at risk for infections unrelated to the reason for admission, including bloodstream and surgical site infections like MRSA (caused by Staphylococcus aureus resistant to methicillin, an antibiotic representative of those which are usually effective against Staphylococcus aureus), bloodstream infections caused by Enterobacteriaceae producing ESBL (extended-spectrum beta-lactamases, enzymes able to destroy some antibiotics), heartvalve infections caused by Enteroccocci resistant to vancomycin, and surgical site and wound infections caused by Acinetobacter baumannii resistant to carbapenems.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="165"> |
|
<prop type="lengthRatio">1.5833333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Meta jkun reżistenti għall-metiċillina (methicillin) (jew għall-oxaċillina [oxacillin], tip ta' peniċillina), jissejjaħ MRSA jew "Staphylococcus aureus reżistenti għall-metiċillina" (Methicillin-Resistant Staphylococcus aureus).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>When it is resistant to methicillin (or to oxacillin, a type of penicillin), it is called MRSA or "Methicillin-Resistant Staphylococcus aureus".</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="166"> |
|
<prop type="lengthRatio">1.24</prop> |
|
<tuv xml:lang="en"> |
|
<seg>coli reżistenti fl-isptarijiet?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>What is Escherichia coli?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="167"> |
|
<prop type="lengthRatio">1.1111111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Kulħadd jista' jiżvolġi rwol importanti fit-tnaqqis tar-reżistenza antibijotika:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Everyone can play an important role in decreasing antibiotic resistance:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="168"> |
|
<prop type="lengthRatio">1.3157894736842106</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-problema hija agħar minn kif kienet fil-passat?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Is the problem worse than in the past?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="169"> |
|
<prop type="lengthRatio">0.3055555555555556</prop> |
|
<tuv xml:lang="en"> |
|
<seg>spiżjara u infermiera:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Doctors and other healthcare professionals, e.g. pharmacists and nurses:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="170"> |
|
<prop type="lengthRatio">1.135</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-antibijotiċi użati għall-kura u l-prevenzjoni ta' infezzjonijiet batteriċi fl-annimali jappartjenu għall-istess gruppi kimiċi ta' dawk li jintużaw fil-bnedmin: makrolidi, tetraċiklini, kwinoloni, beta-lattami, aminoglikosidi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotics used to treat and prevent bacterial infections in animals belong to the same chemical groups as those used for humans: macrolides, tetracyclines, quinolones, beta-lactams, aminoglycosides.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="171"> |
|
<prop type="lengthRatio">0.4796747967479675</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Kulħadd huwa responsabbli li jżomm l-antibijotiċi effikaċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>On this basis, it is important to known when it is appropriate to take antibiotics and how to take antibiotics responsibly.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="172"> |
|
<prop type="lengthRatio">1.063157894736842</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-fatturi ewlenin ta' riskju għal E. coli reżistenti fil-komunità huma kura antibijotika preċedenti.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The main risk factors for resistant E. coli in the community are previous antibiotic treatment.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="173"> |
|
<prop type="lengthRatio">1.069767441860465</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Audience: pubbliku ġenerali</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Audience: general public</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="174"> |
|
<prop type="lengthRatio">1.8</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Lista ta' Kontroll</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Media type</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="175"> |
|
<prop type="lengthRatio">0.8367346938775511</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) tekniki asettiċi u interventi kliniċi,</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) aseptic techniques and clinical interventions,</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="176"> |
|
<prop type="lengthRatio">1.1357142857142857</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Immonitorja kemm huma effettivi miżuri preventivi mmirati biex inaqqsu t-trażmissjoni ta' batterji reżistenti għall-antibijotiċi [82,85] [kunsens tal-esperti].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Monitor how effective targeted preventive measures are at reducing transmission of antibiotic-resistant bacteria [82,85] [expert consensus].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="177"> |
|
<prop type="lengthRatio">1.1411764705882352</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-programm inkluda miżuri għall-kontroll tal-antibijotiċi li jimmiraw l-użu ta' karbapenem [62].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The programme included antibiotic stewardship measures targeting carbapenem use [62].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="178"> |
|
<prop type="lengthRatio">1.3375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) Il-kondiviżjoni tal-informazzjoni dwar il-mikrobijoloġija u x-xejriet tar-reżistenza għall-antibijotiċi;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Sharing information on local microbiology and antibiotic resistance patterns;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="179"> |
|
<prop type="lengthRatio">1.1923076923076923</prop> |
|
<tuv xml:lang="en"> |
|
<seg>f) Tiżgura li l-programmi tal-amministrazzjoni tal-antibijotiċi huma integrati mal-politiki u</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>f) Ensuring antibiotic stewardship programmes are integrated with policies and</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="180"> |
|
<prop type="lengthRatio">1.3523316062176165</prop> |
|
<tuv xml:lang="en"> |
|
<seg>g) Teduka lill-professjonisti tal-kura tas-saħħa rilevanti kollha dwar il-prevenzjoni tal-infezzjonijiet u l-interventi ta' kontroll biex tnaqqas it-trażmissjoni kemm tal-batterji reżistenti għall-antibijotiċi kif ukoll ta' dawk suxxettibbli għall-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>g) Educating all relevant healthcare professionals on infection prevention and control interventions to reduce the transmission of both antibiotic-resistant and antibiotic-susceptible bacteria.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="181"> |
|
<prop type="lengthRatio">1.1951219512195121</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Din il-gwida tista' tinkludi linji gwida, protokolli u listi ta' kontroll [kunsensus tal-esperti].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>This guidance can include guidelines, protocols and checklists [expert consensus].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="182"> |
|
<prop type="lengthRatio">1.231111111111111</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-Greċja - Programm multidimensjonali ta' tliet snin għall-kontroll tal-infezzjonijiet biex jikkontrolla l-firxa tal-batterji reżistenti għal karbapenem f'unità tal-ematoloġija ta' sptar tal-kura terzjarja wassal għal inqas infezzjonijiet ikkawżati minn dawn il-batterji [88].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>3. Greece - A three-year multifaceted infection control programme to control the spread of carbapenem-resistant bacteria in a haematology unit of a tertiary care hospital led to fewer infections caused by these bacteria [88].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="183"> |
|
<prop type="lengthRatio">0.9473684210526315</prop> |
|
<tuv xml:lang="en"> |
|
<seg>f) id-dekontaminazzjoni tal-ambjent,</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>f) decontamination of the environment,</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="184"> |
|
<prop type="lengthRatio">1.1867469879518073</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-Italja - Programm ta' erba' snin għall-kontroll tal-infezzjonijiet naqqas l-inċidenza ta' infezzjonijiet u kolonizzazzjoni kkawżati minn batterji reżistenti għall-karbapenem fi sptar ta' tagħlim.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Italy - A four-year infection control programme decreased the incidence of infections and colonisation caused by carbapenem-resistant bacteria in a teaching hospital.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="185"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Evitaw profilassi antibijotika bla bżonn [31,73].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Avoid unnecessary antibiotic prophylaxis [31,73].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="186"> |
|
<prop type="lengthRatio">1.1528925619834711</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tieħdu sehem b'mod regolari f'korsijiet tat-taħriġ u f'laqgħat li jappoġġjaw l-implimentazzjoni fl-isptar ta': a) użu antibijotiku prudenti, b) linji gwida dwar l-antibijotiċi lokali, ibbażati fuq l-evidenza, u c) miżuri ta' prevenzjoni u ta' kontroll tal-infezzjonijiet [52,53].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Regularly participate in training courses and in meetings that support the implementation in the hospital of: a) prudent antibiotic use, b) evidence-based, local antibiotic guidelines, and c) infection prevention and control measures [52,53].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="187"> |
|
<prop type="lengthRatio">1.2418300653594772</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Iddokumentaw l-indikazzjoni ta' trattament bl-antibijotiku, l-għażla tal-mediċina, id-doża, ir-rotta tal-amministrazzjoni u t-tul ta' żmien tat-trattament fiċ-ċart tal-pazjent [31,42,70,71].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Document the indication of antibiotic treatment, drug choice, dose, route of administration and duration of treatment in the patient chart [31,42,70,71].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="188"> |
|
<prop type="lengthRatio">0.8226950354609929</prop> |
|
<tuv xml:lang="en"> |
|
<seg>għas-sepsis [74], l-infezzjonijiet tal-apparat tal-awrina [103], l-infezzjonijiet tal-ġilda u tat-tessuti rotob [104]) u tapplikaw miżuri tal-prevenzjoni u l-kontroll li huma stabbiliti fl-ambjent tiegħek [31] [kunsens tal-esperti].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Follow antibiotic treatment protocols, based on evidence-based guidelines (e.g. for sepsis [74], urinary tract infections [103], skin and soft tissue infections [104]), and apply infection prevention and control measures that are established in your setting [31] [expert consensus].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="189"> |
|
<prop type="lengthRatio">1.1733333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) Tieħdu l-kulturi rilevanti, qabel ma tibdew it-terapija antibijotika, li tippermetti li t-terapija antibijotika tkun imfassla apposta jew imwaqqfa waqt ir-rikoveru l-isptar;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Taking relevant cultures, before starting antibiotic therapy, which will allow antibiotic therapy to be tailored or stopped during hospitalisation;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="190"> |
|
<prop type="lengthRatio">1.1494252873563218</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-kompiti kliniċi relatati mat-titjib fl-użu tal-antibijotiċi jinkludu [102] [kunsens tal-esperti]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>3. Clinical tasks related to improving antibiotic use include [102] [expert consensus]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="191"> |
|
<prop type="lengthRatio">1.2862068965517242</prop> |
|
<tuv xml:lang="en"> |
|
<seg>a) L-għemil disponibbli ta' linji gwida tal-antibijotiċi tal-isptar abbażi tal-evidenza u mogħdijiet kliniċi għad-dijanjożi, it-trattament u l-ġestjoni tal-iktar infezzjonijiet komuni li tiltaqa' magħhom fid-dipartiment tiegħek (jiġifieri, infezzjonijiet fl-apparat respiratorju, infezzjonijiet tal-ġilda u tat-tessuti rotob, infezzjonijiet fl-apparat tal-awrina u sepsis).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>a) Making available evidence-based hospital antibiotic guidelines and clinical pathways for diagnosing, treating and managing the most common infections encountered in your department (i.e. respiratory tract infections, skin and soft tissue infections, urinary tract infections and sepsis).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="192"> |
|
<prop type="lengthRatio">0.2391304347826087</prop> |
|
<tuv xml:lang="en"> |
|
<seg>infografika</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Adapting the infographic (notes for designers)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="193"> |
|
<prop type="lengthRatio">0.8958333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Napprezzaw kieku l-elementi grafiċi ma jiżdidux, bl-eċċezzjoni ta' logos addizzjonali.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>We would appreciate that graphic elements are not added, with the exception of additional logos.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="194"> |
|
<prop type="lengthRatio">0.8333333333333334</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ir-reżistenza għall-antibijotiċi - theddida dejjem tikber għas-saħħa tal-bniedem</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotic resistance - an increasing threat to human health - Design files - EN - [ZIP-3.71 MB]</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="195"> |
|
<prop type="lengthRatio">0.9772727272727273</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-ECDC lest li jerġa' jiċċekkja l-modifiki.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>ECDC is happy to double check modifications.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="196"> |
|
<prop type="lengthRatio">1.3513513513513513</prop> |
|
<tuv xml:lang="en"> |
|
<seg>124,000 resident għandhom minn tal-inqs HAI waħda;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>124 000 residents have least one HAI.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="197"> |
|
<prop type="lengthRatio">1.2894736842105263</prop> |
|
<tuv xml:lang="en"> |
|
<seg>98,000 pazjent għandhom minn tal-inqas HAI waħda;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>98 000 patients have at least one HAI;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="198"> |
|
<prop type="lengthRatio">1.1836065573770491</prop> |
|
<tuv xml:lang="en"> |
|
<seg>HAIs fl-isptarijiet (pereżempju, il-pulmonite, infezzjonijiet fis-sit kirurġiku u infezzjonijiet fil-fluss tad-demm) normalment huma aktar severi u għandhom impatt akbar minn HAIs fil-faċilitajiet ta' kura fit-tul (pereżempju, infezzjonijiet respiratorji li mhumiex pulmonite, infezzjonijiet fil-kanal tal-awrina, u infezzjonijiet tal-ġilda u tat-tessut artab).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>HAIs in hospitals (for example, pneumonia, surgical site infections and bloodstream infections) are usually more severe and have a higher impact than HAIs in long-term care facilities (for example, respiratory infections other than pneumonia, urinary tract infections and skin and soft tissue infections).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="199"> |
|
<prop type="lengthRatio">1.125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Doża waħda hija normalment biżżejjed għal profilassi kirurġika.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>One dose is usually sufficient for surgical prophylaxis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="200"> |
|
<prop type="lengthRatio">0.9587628865979382</prop> |
|
<tuv xml:lang="en"> |
|
<seg>7 minn 10 antimikrobiċi ġew preskritti għall-kura ta' infezzjoni u 3 minn 10 għal profilassi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>7 in 10 antimicrobials were prescribed for treatment of an infection and 3 in 10 for prophylaxis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="201"> |
|
<prop type="lengthRatio">1.1821305841924399</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Fl-2016-2017, l-ECDC ikkoordina t-tieni stħarriġ dwar il-prevalenza puntwali ta' infezzjonijiet assoċjati mal-kura tas-saħħa u l-użu antimikrobiku fi sptarijiet Ewropej ta' kura akuta u t-tielet stħarriġ dwar il-prevalenza puntwali ta' infezzjonijiet assoċjati mal-kura tas-saħħa u l-użu antimikrobiku fil-faċilitajiet Ewropej ta' kura fit-tul.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>In 2016-2017, ECDC coordinated the second point-prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals and the third point-prevalence survey of healthcare-associated infections and antimicrobial use in European long-term care facilities.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="202"> |
|
<prop type="lengthRatio">1.18</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-bidla minn parenterali għal orali ġiet irrappurtata f'4 % biss tal-preskrizzjonijiet ta' antimikrobiċi parenterali.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Parenteral-to-oral switch was reported in only 4% of the prescriptions of parenteral antimicrobials.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="203"> |
|
<prop type="lengthRatio">1.0573770491803278</prop> |
|
<tuv xml:lang="en"> |
|
<seg>1 minn 10 preskrizzjonijiet antimikrobiċi kienu għall-profilassi medika, li għaliha hemm biss numru limitat ta' indikazzjonijiet.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>1 in 10 antimicrobial prescriptions were for medical prophylaxis, for which there only is a limited number of indications.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="204"> |
|
<prop type="lengthRatio">1.0172413793103448</prop> |
|
<tuv xml:lang="en"> |
|
<seg>7 minn 10 antimikrobiċi ġew amministrati b'mod parenterali.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>7 out of 10 antimicrobials were administered parenterally.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="205"> |
|
<prop type="lengthRatio">1.1294117647058823</prop> |
|
<tuv xml:lang="en"> |
|
<seg>3 minn 4 korsijiet tal-profilassi ngħataw biex jiġu evitati infezzjonijiet fil-kanal tal-awrina.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>3 out of 4 of the prophylaxis courses were given to prevent urinary tract infections.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="206"> |
|
<prop type="lengthRatio">1.1219512195121952</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-proporzjon ta' antibijotiċi b'azzjoni mifruxa varja minn 16 % għal 62 % fl-Ewropa kollha.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The proportion of broad-spectrum antibiotics varied from 16% to 62% across Europe.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="207"> |
|
<prop type="lengthRatio">1.1428571428571428</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Is-sejbiet huma miġbura fil-qosor fi tliet artikli tal-Eurosurveillance:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The findings are summarised in three Eurosurveillance articles:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="208"> |
|
<prop type="lengthRatio">1.196969696969697</prop> |
|
<tuv xml:lang="en"> |
|
<seg>1 minn 24 resident f'faċilità ta' kura fit-tul għandu minn tal-inqas HAI waħda;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>1 in 24 long-term care facilities residents have at least one HAI;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="209"> |
|
<prop type="lengthRatio">0.6275862068965518</prop> |
|
<tuv xml:lang="en"> |
|
<seg>76 % tal-isptarijiet irrappurtaw id-disponibbiltà tal-linji gwida dwar l-użu antimikrobiku.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>76% of hospitals reported the availability of antimicrobial use guidelines. 54% reported some dedicated staff time for antimicrobial stewardship.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="210"> |
|
<prop type="lengthRatio">1.3333333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>1 minn 15-il pazjent tal-isptar għandu minn tal-inqas HAI waħda;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>1 in 15 hospital patients have at least one HAI;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="211"> |
|
<prop type="lengthRatio">0.6271186440677966</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Barra minn hekk, 1 biss minn 5 LTCFs tingħata taħriġ regolari dwar il-preskrizzjoni adegwata ta' antimikrobiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Depending on the country, all or none of the LTCFs have antimicrobial use guidelines. Moreover, only 1 in 5 LTFCs have regular training on appropriate antimicrobial prescribing.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="212"> |
|
<prop type="lengthRatio">1.108695652173913</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-antimikrobiċi normalment jiġu preskritti u jikkontribwixxu għall-iżvilupp ta' reżistenza għall-antimikrobiċi fil-faċilitajiet ta' kura fit-tul (LTCFs).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antimicrobials are commonly prescribed and contribute to the development of antimicrobial resistance in long-term care facilities (LTCFs).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="213"> |
|
<prop type="lengthRatio">1.016260162601626</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Huwa stmat li total ta' 8.9 miljuni HAIs iseħħu kull sena fl-isptarijiet u fil-faċilitajiet Ewropej ta' kura fit-tul f'daqqa.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>A total of 8.9 million HAIs were estimated to occur each year in European hospitals and long-term care facilities combined.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="214"> |
|
<prop type="lengthRatio">1.1081081081081081</prop> |
|
<tuv xml:lang="en"> |
|
<seg>1 minn 2 korsijiet tal-profilassi kirurġika ġie preskritt għal aktar minn ġurnata.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>1 in 2 surgical prophylaxis courses were prescribed for more than one day.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="215"> |
|
<prop type="lengthRatio">1.0344827586206897</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Sir af dwar il-problema tar-reżistenza antibijotika, x'inhu l-kontribut tal-użu tal-antibijotiċi, u kif jista' jiġi promoss l-użu prudenti tal-antibijotiċi u għala għandu jsir dan.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>This infographic highlights the threat that antibiotic resistance poses and the effectiveness of antibiotic stewardship programmes to address the issue from different angles.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="216"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 2 // 14 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 2 // 16 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="217"> |
|
<prop type="lengthRatio">1.625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>l-influwenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Sort by:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="218"> |
|
<prop type="lengthRatio">0.875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Lanqas mhuma l-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Self-medication with antibiotics</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="219"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>infografika -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>infographic -</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="220"> |
|
<prop type="lengthRatio">1.320754716981132</prop> |
|
<tuv xml:lang="en"> |
|
<seg>skeda informattiva, materjal ta' informazzjoni, materjal tat-toolkit -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>infographic, information material, toolkit material -</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="221"> |
|
<prop type="lengthRatio">0.9479166666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>7 / 10 antimikrobiċi ġew preskritti għall-kura ta' infezzjoni u 3 minn 10 għall-profilassi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>7 / 10 antimicrobials were prescribed for treatment of an infection and 3 in 10 for prophylaxis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="222"> |
|
<prop type="lengthRatio">1.3636363636363635</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Issortja skont:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>SAVE LIVES:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="223"> |
|
<prop type="lengthRatio">2.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Niżżel</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>KB]</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="224"> |
|
<prop type="lengthRatio">1.2865168539325842</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Is-sett ta' għodod jinkludi: messaġġi ewlenin, lista ta' kontroll għal preskriventi, fuljetti informattivi, infografika dwar amministrazzjoni ta' antibijotiċi, fuljetti, ittri, kartelluni, preżentazzjoni, kards tal-midja soċjali.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The toolkit includes: key messages, checklist for prescribers, factsheets, infographic about antibiotic stewardship, leaflets, letters, posters, presentation, social media cards.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="225"> |
|
<prop type="lengthRatio">0.5306122448979592</prop> |
|
<tuv xml:lang="en"> |
|
<seg>- Maniġers/amministraturi,</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>- Infection prevention and control professionals,</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="226"> |
|
<prop type="lengthRatio">1.099290780141844</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Dan jirreferi għall-qbil milħuq minn esperti tal-ECDC, membri tal-Kumitat Konsultattiv Tekniku tal-EAAD, u esperti esterni oħrajn u partijiet ikkonċernati.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>This refers to the agreement reached by ECDC experts, EAAD Technical Advisory Committee members, and other external experts and stakeholders.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="227"> |
|
<prop type="lengthRatio">0.9635036496350365</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Uħud mill-messaġġi huma indikati bħala "konsensus espert", minflok ma jkunu marbuta ma' referenza meħuda mil-letteratura xjentifika.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Some of the messages are indicated to be "expert consensus", instead of being linked to a reference taken from the scientific literature.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="228"> |
|
<prop type="lengthRatio">1.25</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-kompiti tiegħek relatati mat-titjib tal-użu tal-antibijotiċi jinkludu [31,56,68,71,83]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Your tasks related to improving antibiotic use include [31,56,68,71,83]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="229"> |
|
<prop type="lengthRatio">0.990909090909091</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ipprovdi rispons u pariri lill-preskriventi dwar l-evalwazzjoni dijanjostika u l-kura tal-mard infettiv [83].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Provide feedback and advice to prescribers on diagnostic evaluation and treatment of infectious diseases [83].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="230"> |
|
<prop type="lengthRatio">0.984375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>b) Tikkollabora mal-ispiżjar tal-isptar u l-mikrobijoloġist kliniku biex timplimenta l-programm ta' kontroll tal-antibijotiċi;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>b) Collaborating with the hospital pharmacist and the clinical microbiologist to implement the antibiotic stewardship programme;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="231"> |
|
<prop type="lengthRatio">1.223529411764706</prop> |
|
<tuv xml:lang="en"> |
|
<seg>f) Taqsam informazzjoni dwar il-mikrobijoloġija lokali u x-xejriet tar-reżistenza għall-antibijotiċi; u,</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>f) Sharing information on local microbiology and antibiotic resistance patterns; and,</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="232"> |
|
<prop type="lengthRatio">1.2035398230088497</prop> |
|
<tuv xml:lang="en"> |
|
<seg>e) Timplimenta linji gwida għall-antibijotiċi tal-isptar ibbażati fuq l-evidenza għal infezzjonijiet komuni u għal profilassi kirurġika;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>e) Implementing evidence-based hospital antibiotic guidelines for common infections and for surgical prophylaxis;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="233"> |
|
<prop type="lengthRatio">1.3298969072164948</prop> |
|
<tuv xml:lang="en"> |
|
<seg>g) Tiġġestixxi l-formularju tal-antibijotiċi tal-isptar tiegħek (jiġifieri, l-lista ta' mediċini disponibbli għall-preskriventi).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>g) Managing your hospital's antibiotic formulary (i.e., list of drugs available for prescribers).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="234"> |
|
<prop type="lengthRatio">1.3214285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Dawn għandhom ikunu disponibbli faċilment u b'mod affidabbli għall-fornituri kollha tal-kura tas-saħħa [56,69].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>These should be readily and reliably accessible to all healthcare providers [56,69].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="235"> |
|
<prop type="lengthRatio">1.3043478260869565</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ħarreġ b'mod regolari lill-preskriventi tal-isptar dwar l-użu prudenti tal-antibijotiku u pparteċipa f'laqgħat dwar l-implimentazzjoni ta' linji gwida tal-antibijotiċi tal-isptar ibbażati fuq l-evidenza [31,53]</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Regularly train hospital prescribers on prudent antibiotic use and participate in meetings on implementing evidence-based hospital antibiotic guidelines [31,53].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="236"> |
|
<prop type="lengthRatio">1.1160714285714286</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tappoġġja l-iżvilupp u l-implimentazzjoni ta' programm tal-amministrazzjoni tal-antibijotiċi fl-organizzazzjoni tiegħek [69].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Support the development and implementation of an antibiotic stewardship programme within your organisation [69].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="237"> |
|
<prop type="lengthRatio">1.247787610619469</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Iċċekkja li l-preskrizzjonijiet tal-antibijotiċi jsegwu protokolli tal-kuri bl-antibijotiċi, ibbażati fuq linji gwida bbażati fuq l-evidenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>4. Check that antibiotic prescriptions follow antibiotic treatment protocols, based on evidence-based guidelines.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="238"> |
|
<prop type="lengthRatio">0.7727272727272727</prop> |
|
<tuv xml:lang="en"> |
|
<seg>pubbliku ġenerali</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>primary care providers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="239"> |
|
<prop type="lengthRatio">1.2266666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mudell għal djalogu mal-pazjent ibbażat fuq l-evidenza disponibbli jipprovdi linji gwida u appoġġ għat-tobba li joħorġu riċetti fis-settur tal-kura primarja li jiltaqgħu ma' pressjoni mill-pazjent għall-antibijotiċi, u jippromowovi l-użu xieraq tal-antibijotiċi mill-pazjenti.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>A model for a patient dialogue on the basis of available evidence provides guidance and support for primary care prescribers who encounter patient pressure for antibiotics, and promotes appropriate antibiotic use by patients.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="240"> |
|
<prop type="lengthRatio">1.3918918918918919</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Dan jista' jintuża bħala skeda informattiva jew bħala messaġġ ta' tfakkira waqt il-konsulatazzjonijiet.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>It can be used as a fact sheet or as a desk reminder during consultations.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="241"> |
|
<prop type="lengthRatio">0.1935483870967742</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Niżżel</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Twitter Facebook Linked In Mail</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="242"> |
|
<prop type="lengthRatio">1.3</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 2 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 3 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="243"> |
|
<prop type="lengthRatio">1.0275229357798166</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-infografika tispjega x'inhi r-reżistenza għall-antibjotiċi u tenfasizza l-firxa tal-problemi li qed naffaċċjaw minħabba r-reżistenza għall-antibjotiċi u l-konsum tal-antibijotiċi fil-bnedmin - fi sptarijiet u fil-komunità.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The infographic explains what antibiotic resistance is and highlights the extent of the problems that we are facing due to antibiotic resistance and antibiotic consumption in humans - in hospitals and in the community.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="244"> |
|
<prop type="lengthRatio">0.9215686274509803</prop> |
|
<tuv xml:lang="en"> |
|
<seg>JUM EWROPEW GĦALL-GĦARFIEN DWAR L-ANTIBIJOTIĊI</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Infographic about antibiotic stewardship programmes</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="245"> |
|
<prop type="lengthRatio">1.2394366197183098</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Jekk ikollkom dubju, ikkonsultaw mat-tim tal-kontroll tal-antibijotiċi [31,42,53,70,71]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>If in doubt, consult with antibiotic stewardship team [31,42,53,70,71]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="246"> |
|
<prop type="lengthRatio">1.1122448979591837</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• Tfittxu gwida u parir mingħand kollega superjuri jew mingħand membru tat-tim tal-kontroll tal-antibijotiċi;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>• Seek guidance and advice from a senior colleague or a member of the antibiotic stewardship team;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="247"> |
|
<prop type="lengthRatio">1.2483660130718954</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tiddokumentaw l-indikazzjoni ta' trattament bl-antibijotiku, l-għażla tal-mediċina, id-doża, ir-rotta tal-amministrazzjoni u t-tul ta' żmien tat-trattament fiċ-ċart tal-pazjent [31,42,70,71].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Document the indication of antibiotic treatment, drug choice, dose, route of administration and duration of treatment in the patient chart [31,42,70,71].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="248"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Messaġġi ewlenin għal tobba żgħar u studenti</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for junior doctors and students</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="249"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>a) Hemm probabbiltà għolja ta' infezzjoni batterika, iktar milli kolonizzazzjoni jew infezzjoni virali?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>a) Is there a high probability of a bacterial infection, rather than colonisation or a viral infection?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="250"> |
|
<prop type="lengthRatio">1.0941176470588236</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Kun żgur li l-pazjenti (u l-familji tagħhom) jifhmu r-raġuni għat-terapija bl-antibijotiku u l-punti ewlenin relatati mal-użu tal-antibijotiku, inkluż biex [31,69] [kunsens tal-esperti]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Ensure that patients (and their families) understand the reason for antibiotic therapy, and key points related to antibiotic use, including to [31,69] [expert consensus]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="251"> |
|
<prop type="lengthRatio">0.9493670886075949</prop> |
|
<tuv xml:lang="en"> |
|
<seg>b) Inġabru l-kulturi xierqa qabel ingħatat bidu t-terapija bl-antibijotiċi?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>b) Have the appropriate cultures been taken before starting antibiotic therapy?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="252"> |
|
<prop type="lengthRatio">1.0125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Qabel ma tippreskrivu antibijotiku, għandkom [25,26,53,70] [kunsens tal-esperti]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Before you prescribe an antibiotic, you should [25,26,53,70] [expert consensus]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="253"> |
|
<prop type="lengthRatio">0.971830985915493</prop> |
|
<tuv xml:lang="en"> |
|
<seg>d) Il-pazjent għandu infezzjoni li se tirrispondi għall-antibijotiċi?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>d) Does the patient have an infection that will respond to antibiotics?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="254"> |
|
<prop type="lengthRatio">1.0926829268292684</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Meta taraw antibijotiku preskritt, staqsu lill-preskrivent dwar l-indikazzjoni, l-għażla, id-doża, ir-rotta tal-amministrazzjoni u t-tul tat-trattament, biex tifhmu jekk dan huwiex isegwi l-linji gwida tal-antibijotiċi [69].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>When you see an antibiotic prescribed, ask the prescriber about the indication, choice, dose, route of administration and duration of treatment, to understand if this is follows antibiotic guidelines [69].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="255"> |
|
<prop type="lengthRatio">1.1397379912663756</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) Iċċekkjajt għall-użu riċenti tal-antibijotiċi, l-allerġiji għall-mediċini, l-użu tat-terapija immunosuppressiva, rikoveru l-isptar jew istituzzjonalizzazzjoni riċenti, vjaġġar riċenti barra mill-Ewropa u r-riżultati tal-mikrobijoloġija għat-3 xhur ta' qabel?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Have you checked for recent antibiotic use, drug allergies, use of immunosuppressive therapy, recent hospitalisation or institutionalisation, recent travel outside of Europe, and microbiology results for the previous 3 months?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="256"> |
|
<prop type="lengthRatio">1.2380952380952381</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) Qatt ma jużaw antibijotiċi li jkun fadlilhom minn trattamenti preċedenti; u</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Never use leftover antibiotics from previous treatments; and</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="257"> |
|
<prop type="lengthRatio">1.303030303030303</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Irrispondu l-mistoqsijiet ewlenin li ġejjin biex tottimizzaw it-terapija antibijotika.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Answer the following key questions to optimise antibiotic therapy.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="258"> |
|
<prop type="lengthRatio">1.1944444444444444</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-kompiti tagħkom relatati mat-titjib tal-użu antibijotiku jinkludu [42,56,76,94,95]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Your tasks related to improving antibiotic use include [42,56,76,94,95]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="259"> |
|
<prop type="lengthRatio">1.3636363636363635</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Affarijiet li għandek tkun taf</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Things you should know</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="260"> |
|
<prop type="lengthRatio">1.0507246376811594</prop> |
|
<tuv xml:lang="en"> |
|
<seg>b) Tikkollaboraw mal-ispeċjalista tal-mard infettiv u mal-mikrobijoloġista kliniku biex timplimentaw il-programm għall-kontroll tal-antibijotiċi;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>b) Collaborating with the infectious disease specialist and the clinical microbiologist to implement the antibiotic stewardship programme;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="261"> |
|
<prop type="lengthRatio">1.2024539877300613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-forom ta' ordni speċjali jillimitaw it-tul tal-profilassi antibijotika perioperattiva u jnaqqsu l-inċidenza tal-infezzjonijiet tal-postijiet kirurġiċi, l-użu u l-ispejjeż tal-antibijotiċi [56].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Special order forms limit the duration of perioperative antibiotic prophylaxis and reduce the incidence of surgical site infections, antibiotic use and costs [56].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="262"> |
|
<prop type="lengthRatio">1.28</prop> |
|
<tuv xml:lang="en"> |
|
<seg>h) Tiġġestixxu l-formularju antimikrobjali tal-isptar tagħkom (jiġifieri, il-lista tal-mediċini disponibbli għall-preskriventi).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>h) Managing your hospital's antimicrobial formulary (i.e., list of drugs available for prescribers).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="263"> |
|
<prop type="lengthRatio">1.248062015503876</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tipprovdu rispons u pariri lill-preskriventi dwar l-għażla tal-antibijotiċi, id-doża, l-ottimizzazzjoni tat-tul taż-żmien u r-rotta tal-amministrazzjoni [31,94].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Provide feedback and advice to prescribers on antibiotic choice, dose, duration optimisation and route of administration [31,94].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="264"> |
|
<prop type="lengthRatio">1.3173652694610778</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ħarrġu b'mod regolari lill-preskriventi ta' sptar dwar l-użu prudenti tal-antibijotiċi u pparteċipaw f'laqgħat dwar l-implimentazzjoni ta' linji gwida dwar l-antibijotiċi tal-isptar ibbażati fuq l-evidenza [31,53,94,95].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Train hospital prescribers regularly on prudent antibiotic use and participate in meetings on implementing evidence-based hospital antibiotic guidelines [31,53,94,95].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="265"> |
|
<prop type="lengthRatio">0.5666666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>it-tnaqqis tat-tul tat-terapija parenterali, mingħajr ma jħalli impatt fuq ir-riżultati kliniċi) [56].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>3. Pharmacist-led parenteral-to-oral switches improve clinical outcomes (e.g. shortening the duration of parenteral therapy without negatively impacting on clinical outcomes) [56].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="266"> |
|
<prop type="lengthRatio">0.7857142857142857</prop> |
|
<tuv xml:lang="en"> |
|
<seg>INIZJATTIVA EWROPEA DWAR IS-SAĦĦA</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: materiālu rīkkopa</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="267"> |
|
<prop type="lengthRatio">1.1714285714285715</prop> |
|
<tuv xml:lang="en"> |
|
<seg>f) Tevalwaw mill-ġdid it-trattament wara 48-72 siegħa jew meta jkunu disponibbli r-riżultati mill-kampjuni mikrobijoloġiċi;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>f) Re-evaluating treatment after 48-72 hours, or when results from microbiological samples are available;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="268"> |
|
<prop type="lengthRatio">1.7647058823529411</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Affarijiet li għandek tkun taf</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Things you can do</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="269"> |
|
<prop type="lengthRatio">1.098159509202454</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Aċċertaw li l-pazjenti (u l-familji tagħhom) jifhmu r-raġunijiet għat-terapija antibijotika u l-punti ewlenin relatati mal-użu tal-antibijotiċi, inkluż biex [kunsens tal-esperti]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Ensure that patients (and their families) understand the reasons for antibiotic therapy, and key points related to antibiotic use, including to [expert consensus]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="270"> |
|
<prop type="lengthRatio">1.1049723756906078</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) Tiddokumentaw l-indikazzjoni għall-kura tal-antibijotiċi, l-għażla tal-mediċina, id-doża, ir-rotta tal-amministrazzjoni u t-tul tat-trattament, fiċ-ċart tal-pazjent, meta tippreskrivi antibijotiku;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Documenting the indication for antibiotic treatment, drug choice, dose, route of administration and duration of treatment, in the patient chart, when you prescribe an antibiotic;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="271"> |
|
<prop type="lengthRatio">1.2203389830508475</prop> |
|
<tuv xml:lang="en"> |
|
<seg>h) Tikkunsidraw ix-xejriet ta' reżistenza għall-antibijotiċi u l-mikrobijoloġija lokali meta tippreskrivu trattamenti tal-antibijotiċi empiriċi;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>h) Considering local microbiology and antibiotic resistance patterns when prescribing empirical antibiotic treatments;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="272"> |
|
<prop type="lengthRatio">1.25</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Bħala preskriventi tal-isptar, il-kompiti tagħkom relatati mat-titjib fl-użu tal-antibijotiċi jinkludu li [31,42,43,52-54,56,70,71,90]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>As hospital prescribers your tasks related to improving antibiotic use include [31,42,43,52-54,56,70,71,90]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="273"> |
|
<prop type="lengthRatio">1.144927536231884</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-preskrizzjoni tal-iktar trattament tal-antibijotiku qasir ibbażat fuq l-evidenza jnaqqas il-feġġa ta' batterji reżistenti għall-antibijotiċi [54,56,71,91].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Prescribing the shortest evidence-based duration of antibiotic treatment reduces emergence of antibiotic-resistant bacteria [54,56,71,91].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="274"> |
|
<prop type="lengthRatio">1.1513157894736843</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Qlib immexxi minn spiżjar minn parenterali għal orali rriżulta f'tul taż-żmien iqsar tat-terapija parenterali mingħajr ma ħallia impatt negattiv fuq ir-riżultati kliniċi [56].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>9. A pharmacist-led parenteral-to-oral switch resulted in shortened parenteral therapy durations without negatively impacting on clinical outcomes [56].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="275"> |
|
<prop type="lengthRatio">1.0950920245398772</prop> |
|
<tuv xml:lang="en"> |
|
<seg>b) Tidentifikaw l-isfond tal-pazjenti individwali rilevanti meta tevalwaw il-bżonn ta' preskrizzjoni antibijotika, inkluż l-użu riċenti tal-antibijotiċi, allerġiji għall-mediċini, l-użu ta' terapija immunosoppressiva, rikoveru l-isptar jew istituzzjonalizzazzjoni reċenti, vjaġġar riċenti barra mill-Ewropa u riżultati mikrobijoloġiċi għat-3 xhur ta' qabel;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>b) Identifying relevant individual patient background when evaluating the need for an antibiotic prescription, including recent antibiotic use, drug allergies, use of immunosuppressive therapy, recent hospitalisation or institutionalisation, recent travel outside of Europe, and microbiology results for the previous 3 months;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="276"> |
|
<prop type="lengthRatio">1.1521739130434783</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It-tempiżmu korrett u t-tul ottimali tal-profilassi tal-antibijotiċi għall-kirurġija jwassal għal inqas infezzjonijiet fuq il-post tal-kirurġija u jnaqqas il-feġġa ta' batterji reżistenti għall-antibijotiċi [73].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>5. Correct timing and optimal duration of antibiotic prophylaxis for surgery leads to fewer surgical site infections, and decreases the emergence of antibiotic-resistant bacteria [73].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="277"> |
|
<prop type="lengthRatio">1.048780487804878</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Remove this filter Type: netwerks u sħubiji</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Remove this filter Type: toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="278"> |
|
<prop type="lengthRatio">2.2</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Dwar il-jum</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>About</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="279"> |
|
<prop type="lengthRatio">1.1875</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-Jum Ewropew għall-Għarfien dwar l-Antibijotiċi huwa inizjattiva Ewropea dwar is-saħħa pubblika li tiġi organizzata fit-18 ta' Novembru ta' kull sena sabiex jitqajjem għarfien dwar it-theddida għas-saħħa pubblika mir-reżistenza għall-antibijotiċi u l-użu prudenti ta' l-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The European Antibiotic Awareness Day is an annual European public health initiative that takes place on 18 November to raise awareness about the threat to public health of antibiotic resistance and the importance of prudent antibiotic use.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="280"> |
|
<prop type="lengthRatio">1.2876712328767124</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-użu prudenti ta' l-antibijotiċi jista' jgħin biex iwaqqaf il-batterji reżistenti milli jiżviluppaw u jgħin sabiex l-antibijotiċi jinżammu effettivi għall-użu min ġenerazzjonijiet futuri.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Prudent use of antibiotics can help stop resistant bacteria from developing and help keep antibiotics effective for the use of future generations.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="281"> |
|
<prop type="lengthRatio">1.0842105263157895</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-aħħar data tikkonferma li madwar l-Unjoni Ewropea, in-numru ta' pazjenti nfettati mill-batterji reżistenti qiegħed jiżdied u li r-reżistenza għall-antibijotiċi hija ta' theddida kbira għas-saħħa pubblika.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The latest data confirms that across the European Union the number of patients infected by resistant bacteria is increasing and that antibiotic resistance is a major threat to public health.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="282"> |
|
<prop type="lengthRatio">1.196078431372549</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• 65 % irrappurtaw tnaqqis fit-tul tas-soġġorn jew mortalità;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>• 65% reported reduced length of stay or mortality;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="283"> |
|
<prop type="lengthRatio">1.105263157894737</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• Jintuża spettru wiesa' tal-antibijotiċi;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>• Broad-spectrum antibiotics are used;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="284"> |
|
<prop type="lengthRatio">1.194915254237288</prop> |
|
<tuv xml:lang="en"> |
|
<seg>- Il-pazjenti għandhom riskju ikbar ta' 24 % tal-mortalità bi kwalunkwe infezzjoni Pseudomonas aeruginosa reżistenti għall-antibijotiċi [13].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>- Patients have a 24% increased risk of mortality with any antibiotic-resistant Pseudomonas aeruginosa infection [13].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="285"> |
|
<prop type="lengthRatio">1.1136363636363635</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Batterji gram-negattivi, bħalma huma Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa u Acinetobacter spp., qegħdin isiru reżistenti għall-maġġoranza tal-antibijotiċi disponibbli [16,17].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Gram-negative bacteria, such as Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa, and Acinetobacter spp., are becoming resistant to most available antibiotics [16,17].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="286"> |
|
<prop type="lengthRatio">1.0277777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• 80 % irrappurtaw tnaqqis fin-nefqa;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>• 80% reported reduced expenditures;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="287"> |
|
<prop type="lengthRatio">1.1372549019607843</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) It-tnaqqis fl-episodji avversi mill-użu antibijotiku; u</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Reducing adverse events from antibiotic use; and</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="288"> |
|
<prop type="lengthRatio">1.0897435897435896</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Id-direttorju tal-ECDC (link) jinkludi riżorsi onlajn għall-iżvilupp ta' linji gwida.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The ECDC directory (link) contains online resources for developing guidelines.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="289"> |
|
<prop type="lengthRatio">1.2771084337349397</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Programmi dwar il-kontroll tal-antibijotiċi jistgħu jikkontribwixxu għal [42,45,46] [kunsens tal-esperti]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotic stewardship programmes, can contribute to [42,45,46] [expert consensus]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="290"> |
|
<prop type="lengthRatio">1.2123893805309736</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-programmi dwar il-kontroll tal-antibijotiċi jistgħu jnaqqsu b'suċċess ir-rati tal-infezzjoni b'Clostridium difficile [19,22,43,44,48].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotic stewardship programmes can successfully reduce Clostridium difficile infection rates [19,22,43,44,48].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="291"> |
|
<prop type="lengthRatio">1.1694915254237288</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• 96 % tal-isptarijiet irrappurtaw ħruġ ta' riċetta inqas inadegwata;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>• 96% hospitals reported reduced inappropriate prescribing;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="292"> |
|
<prop type="lengthRatio">1.3214285714285714</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• 71 % irrappurtaw tnaqqis fl-infezzjonijiet assoċjati mal-kura tas-saħħa;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>• 71% reported reduced healthcare-associated infections;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="293"> |
|
<prop type="lengthRatio">1.0982142857142858</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) Inqas trattamenti antibijotiċi effettivi għal pazjenti immunosuppressi u dawk li jgħaddu minn operazzjonijiet kirurġiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Fewer effective antibiotic treatments for immunosuppressed patients and those undergoing surgical operations;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="294"> |
|
<prop type="lengthRatio">1.1627906976744187</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-inizjattivi ta' ġestjoni antimikrobjali li jippromwovu l-użu antibijotiku prudenti jissejjħu programmi dwar il-kontroll tal-antibijotiċi [19,42-45].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antimicrobial management initiatives that promote prudent antibiotic use are called antibiotic stewardship programmes [19,42-45].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="295"> |
|
<prop type="lengthRatio">1.167741935483871</prop> |
|
<tuv xml:lang="en"> |
|
<seg>e) It-terapija antibijotika ma tiġix riveduta wara 48-72 siegħa; jew l-għażla tal-antibijotiku ma tiġix issimplifikata meta ir-riżultat tal-kultura mikrobijoloġika jsir disponibbli.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>e) Antibiotic therapy is not reviewed after 48-72 hours, or the choice of antibiotic is not streamlined when microbiological culture data become available.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="296"> |
|
<prop type="lengthRatio">1.196078431372549</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• 58 % irrappurtaw tnaqqis fir-reżistenza għall-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>• 58% reported reductions in antibiotic resistance.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="297"> |
|
<prop type="lengthRatio">1.1879699248120301</prop> |
|
<tuv xml:lang="en"> |
|
<seg>e) Taħriġ u edukazzjoni għall-persunal mediku, farmaċewtiku, tal-laboratorju, tal-infermiera u dak mhux kliniku, kif ukoll għall-pazjenti u l-familji tagħhom;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>e) Training and education for medical, pharmacy, laboratory, nursing, and non-clinical staff, as well as patients and their families;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="298"> |
|
<prop type="lengthRatio">1.245</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Fl-isptarijiet Ewropej, l-infezzjonijiet b'Clostridium difficile jistgħu jwasslu sa żieda ta' 42 % fil-mortalità, 19-il jum addizzjonali ta' soġġorn fl-isptarijiet u iktar minn EUR 14,000 ta' spejjeż kostijiet addizzjonali għal kull pazjent [23,24].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>In European hospitals, Clostridium difficile infections can lead to up to a 42% increase in mortality, 19 extra days of hospital stay, and more than EUR 14,000 of additional costs per patient [23,24].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="299"> |
|
<prop type="lengthRatio">1.4</prop> |
|
<tuv xml:lang="en"> |
|
<seg>b) Iż-żieda fir-rati tal-kura tal-infezzjonijiet u t-tnaqqis fil-fallimenti tat-trattament;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>b) Increasing infection cure rates and reduce treatment failures;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="300"> |
|
<prop type="lengthRatio">1.0389610389610389</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Spanja - Wara sena waħda biss, l-edukazzjoni dwar il-linji gwida flimkien ma' rispons regolari irriżultat f'titjib ta' 26 % fir-rata ta' trattamenti adegwati u fi tnaqqis ta' 42 % tal-konsum antibijotiku fi sptar ta' tagħlim terzjarju [67].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Spain - After only one year, education on guidelines combined with regular feedback led to a 26% improvement in the rate of appropriate treatments, and a 42% reduction of antibiotic consumption at a tertiary teaching hospital [67].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="301"> |
|
<prop type="lengthRatio">1.2359550561797752</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-użu ħażin tal-antibijotiċi jżid l-inċidenza ta' infezzjonijiet ikkawżati minn Clostridium difficile [19-22].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Misusing antibiotics increases the incidence of Clostridium difficile infections [19-22].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="302"> |
|
<prop type="lengthRatio">1.0481283422459893</prop> |
|
<tuv xml:lang="en"> |
|
<seg>a) Dewmien fl-aċċess għal terapija antibijotika effettiva għal pazjenti individwali, jikkawża fallimenti fit-trattament, mard itwal, rikoveru mtawwal fl-isptar u żieda fil-morbidità u l-mortalità;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>a) Delayed access to effective antibiotic therapy for individual patients, causing treatment failures, longer illnesses, prolonged stays in hospital and increased morbidity and mortality;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="303"> |
|
<prop type="lengthRatio">1.1465968586387434</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-Polonja - L-iżvilupp ta' linji gwida għal riċetti għal antibijotiċi u approvazzjoni ta' awtorizzazzjoni minn qabel għal antibijotiċi ristretti naqqas il-konsum totali ta' antibijotiċi f'sala pedjatrika ġenerali [66].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Poland - Developing guidelines for antibiotic prescriptions and pre-authorisation approval for restricted antibiotics decreased total antibiotic consumption in a general paediatric ward [66].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="304"> |
|
<prop type="lengthRatio">1.1072961373390557</prop> |
|
<tuv xml:lang="en"> |
|
<seg>In-NetherlandsL-Olanda - Verifiki tal-każijiet għall-valutazzjoni mill-ġdid tal-użu wara 48 siegħa naqqsu l-konsum tal-antibijotiċi u t-tul ta' rikoveru f'unità uroloġika ta' sptar akkademiku u kellhom ukoll redditu pożittiv dirett fuq l-investiment [64,65].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Netherlands - Case audits for the reassessment of antibiotic use after 48 hours reduced antibiotic consumption and length of stay in a urology ward of an academic hospital, and also had a positive direct return on investment [64,65].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="305"> |
|
<prop type="lengthRatio">1.1754385964912282</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• 86 % irrappurtaw tnaqqis fl-użu ta' antibijotiċi b'firxa wiesgħa;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>• 86% reported reduced use of broad-spectrum antibiotics;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="306"> |
|
<prop type="lengthRatio">1.075</prop> |
|
<tuv xml:lang="en"> |
|
<seg>d) Verifika proattiva ta' preskrizzjonijiet antibijotiċi b'rispons lil membri tat-tim;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>d) Proactive auditing of antibiotic prescriptions with feedback to team members;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="307"> |
|
<prop type="lengthRatio">1.0217391304347827</prop> |
|
<tuv xml:lang="en"> |
|
<seg>b) Il-ħatra ta' mexxejja li huma responsabbli għall-programm globali u għall-użu antibijotiku.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>b) Appointing leaders that are responsible for the overall programme and for antibiotic use.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="308"> |
|
<prop type="lengthRatio">0.9897435897435898</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Franza - L-użu ristrett ta' fluworokinolon naqqas il-konsum ta' din il-klassi ta' antibijotiċi u naqqas ir-rata ta' Staphylococcus aureus reżistenti għall-metiċillina fi sptar ta' tagħlim [58].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>22. France - Restricting use of fluoroquinolones reduced consumption of this class of antibiotics and decreased the rate of meticillin-resistant Staphylococcus aureus in a teaching hospital [58].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="309"> |
|
<prop type="lengthRatio">0.7777777777777778</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Applika</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>IN EUROPE</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="310"> |
|
<prop type="lengthRatio">1.2647058823529411</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 11 minn 11 // 108 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 11 of 30 // 291 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="311"> |
|
<prop type="lengthRatio">1.625</prop> |
|
<tuv xml:lang="en"> |
|
<seg>infografika -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Sort by:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="312"> |
|
<prop type="lengthRatio">1.6818181818181819</prop> |
|
<tuv xml:lang="en"> |
|
<seg>fornituri tal-kura tas-saħħa primarja</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>primary care providers</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="313"> |
|
<prop type="lengthRatio">1.45</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Avveniment dirett fuq Twitter</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Global Twitter storm</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="314"> |
|
<prop type="lengthRatio">2.6724137931034484</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Jekk tixtieq tappoġġja l-kampanja, ixxerred messaġġi, stampi jew vidjos matul il-ġimgħa tat-12-18 ta' Novembru 2018, uża l-hashtag #KeepAntibioticsWorking.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>November 2019, using the hashtag #KeepAntibioticsWorking .</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="315"> |
|
<prop type="lengthRatio">1.1006711409395973</prop> |
|
<tuv xml:lang="en"> |
|
<seg>70 sena biss wara l-introduzzjoni tal-antibijotiċi, qegħdin niffaċċjaw il-possibbiltà ta' futur mingħajr mediċini effettivi għall-kura ta' infezzjonijiet batteriċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Only 70 years after the introduction of antibiotics, we are facing the possibility of a future without effective drugs to treat bacterial infections.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="316"> |
|
<prop type="lengthRatio">0.7058823529411765</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ir-reżistenza għall-antibijotiċi - fejn wasalna?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>#EAAD, #AntibioticResistance, #Antibiotics & #KeepAntibioticsWorking</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="317"> |
|
<prop type="lengthRatio">1.5384615384615385</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Stejjer ta' pazjenti</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="318"> |
|
<prop type="lengthRatio">1.2424242424242424</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Mingħajr #antibijotiċi, mhux se nkunu nistgħu nindirizzaw infezzjonijiet sempliċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Without #antibiotics, we won't be able to treat simple infections.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="319"> |
|
<prop type="lengthRatio">1.1022727272727273</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pazjenti, tobba, infermiera: kulħadd huwa responsabbli sabiex juża l-antibijotiċi b'mod prudenti.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Patients, doctors, nurses: it is everyone's responsibility to use antibiotics prudently.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="320"> |
|
<prop type="lengthRatio">1.3984375</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-użu prudenti ta' #antibijotiċi u l-prevenzjoni u l-kontroll ta' infezzjonijiet jistgħu jiġġieldu kontra #Reżistenzagħall-Antibijotiċi u jgħinu rigward #Żomml-AntibijotiċiJaħdmu.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Prudent use of #antibiotics and infection prevention & control can fight #AntibioticResistance and help #KeepAntibioticsWorking.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="321"> |
|
<prop type="lengthRatio">1.0833333333333333</prop> |
|
<tuv xml:lang="en"> |
|
<seg>#Żomml-AntibijotiċiJaħdmu.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>#KeepAntibioticsWorking.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="322"> |
|
<prop type="lengthRatio">1.2346938775510203</prop> |
|
<tuv xml:lang="en"> |
|
<seg>#Antibijotiċi huma effettivi biss kontra infezzjonijiet batteriċi u ma jistgħux jgħinu f'każ ta' irjiħat jew #influwenza.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>#Antibiotics are only effective against bacterial infections and cannot help against cold or #flu.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="323"> |
|
<prop type="lengthRatio">1.1428571428571428</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Messaġġi ewlenin għall-pubbliku ġenerali</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for the general public</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="324"> |
|
<prop type="lengthRatio">1.0845070422535212</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-antibijotiċi spiss jikkawżaw effetti sekondarji bħal dijarrea [1, 2, 7, 8].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotics often give you side effects such as diarrhoea [1, 2, 7, 8].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="325"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Iżżommx kuri ta' antibijotiċi li jifdallek [10].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Do not keep leftover antibiotic treatments [10].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="326"> |
|
<prop type="lengthRatio">1.1</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-antibijotiċi huma effikaċi biss kontra infezzjonijiet batteriċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotics are effective only against bacterial infections.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="327"> |
|
<prop type="lengthRatio">1.125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-użu ta' antibijotiċi jġiegħel lill-batterji jsiru reżistenti għall-kuri antibijotiċi [3, 4, 5], għaldaqstant huwa importanti li ma tiħux antibijotiċi għar-raġunijiet żbaljati jew b'mod inkorrett [1, 2, 9].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotic use causes bacteria to become resistant to antibiotic treatments [3, 4, 5], therefore it is important not to take antibiotics for the wrong reasons or incorrectly [1, 2, 9].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="328"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Meta għandi nieħu antibijotiċi?</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>When should I take antibiotics?</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="329"> |
|
<prop type="lengthRatio">1.2040816326530612</prop> |
|
<tuv xml:lang="en"> |
|
<seg>infografika materjal ta' informazzjoni materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>infographic information material toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="330"> |
|
<prop type="lengthRatio">1.054054054054054</prop> |
|
<tuv xml:lang="en"> |
|
<seg>70 sena biss wara l-introduzzjoni tal-antibijotiċi, qegħdin naffaċċjaw il-possibbiltà ta' futur mingħajr antibijotiċi effettivi għat-trattament ta' pazjenti infettati b'diversi tipi ta' batterji.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Only 70 years after the introduction of antibiotics, we are facing the possibility of a future without effective antibiotics for treating patients infected by several types of bacteria.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="331"> |
|
<prop type="lengthRatio">1.1290322580645162</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-konsum tal-antibjotiċi jvarja ħafna bejn il-pajjiżi tal-UE/taż-ŻEE.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Antibiotic consumption varies widely between EU/EEA countries.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="332"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Barra minn hekk, l-infografika turi l-perċentwali ta' reżistenza kontra l-aktar gruppi ta' antibijotiċi komuni.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Furthermore, the infographic shows the percentages of resistance against the most common groups of antibiotics.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="333"> |
|
<prop type="lengthRatio">1.1282051282051282</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• Tnaqqis tal-konsum tal-antibijotiċi b'20%,</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Reducing antibiotic consumption by 20%,</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="334"> |
|
<prop type="lengthRatio">1.4242424242424243</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• Tnaqqis tal-ispejjeż tal-antibijotiċi bi 33%.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Reducing antibiotic costs by 33%.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="335"> |
|
<prop type="lengthRatio">1.1323529411764706</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-implementazzjoni ta' programmi ta' kontroll antibijotiku rriżultat fi [46]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Implementing antibiotic stewardship programmes has resulted in [46]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="336"> |
|
<prop type="lengthRatio">1.1944444444444444</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-kompiti tiegħek relatati mat-titjib tal-użu antibijotiku jinkludu [31,42,56,71,75]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Your tasks related to improving antibiotic use include [31,42,56,71,75]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="337"> |
|
<prop type="lengthRatio">1.0601092896174864</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tipprovdi fondi u riżorsi għall-programm tal-kontroll tal-antibijotiċi (inkluż eż., salarji għal persunal iddedikat, kapaċitajiet tal-IT, testijiet dijanjostiċi rapidi u ta' punt ta' kura) [31].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>13. Provide funds and resources for an antibiotic stewardship programme (including e.g., salaries for dedicated staff, IT capabilities, rapid and point-of-care diagnostic tests) [31].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="338"> |
|
<prop type="lengthRatio">1.0606060606060606</prop> |
|
<tuv xml:lang="en"> |
|
<seg>c) L-implimentazzjoni ta' attivitajiet u taħriġ edukattivi mmirati li:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>c) Implementing targeted educational activities and training that:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="339"> |
|
<prop type="lengthRatio">1.0890410958904109</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-ispeċjalisti tal-mard infettiv, il-mikrobijoloġisti kliniċi u l-ispiżjara kliniċi huma kollha mexxejja ewlenin fit-tim tal-kontroll tal-antibijotiċi [56,76].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Infectious disease specialists, clinical microbiologists, and clinical pharmacists are all key leaders in the antibiotic stewardship team [56,76].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="340"> |
|
<prop type="lengthRatio">1.1953125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>e) Tistabbilixxi indikaturi tal-kwalità u metriċi tal-kwantità biex tkejjel il-progress u r-riżultati tal-programm tal-amministrazzjoni tal-antibijotiċi;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>e) Setting quality indicators and quantity metrics to measure the progress and outcomes of the antibiotic stewardship programme;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="341"> |
|
<prop type="lengthRatio">0.9848484848484849</prop> |
|
<tuv xml:lang="en"> |
|
<seg>i. tottimizza l-ġestjoni dijanjostika u terapewtika tal-pazjenti;</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>i. optimise the diagnostic and therapeutic management of patients;</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="342"> |
|
<prop type="lengthRatio">1.184782608695652</prop> |
|
<tuv xml:lang="en"> |
|
<seg>a) L-istabbiliment ta' tim multidixxiplinarju għall-programm tiegħek ta' kontroll tal-antibijotiċi fl-isptar.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>a) Establishing a multidisciplinary team for your hospital antibiotic stewardship programme.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="343"> |
|
<prop type="lengthRatio">1.1965811965811965</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• deċiżjonijiet appoġġjati mill-kompjuter, li jorbtu l-indikazzjoni klinika, id-dejta mikrobijoloġika u l-preskrizzjoni ta' dejta flimkien u</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>computer-supported decisions, which link clinical indication, microbiological data and prescribing data together, and</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="344"> |
|
<prop type="lengthRatio">1.2293577981651376</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tagħti prijorità lill-kontroll tal-antibijotiċi u l-politiki tal-prevenzjoni u l-kontroll tal-infezzjonijiet, kif ukoll strateġiji u attivitajiet li jappoġġjaw l-użu prudenti tal-antibijotiċi u li jipprevjenu l-firxa tal-batterji reżistenti għall-antibijotiċi [31,71].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Prioritise antibiotic stewardship and infection prevention and control policies, as well as strategies and activities that support prudent antibiotic use and prevent the spread of antibiotic-resistant bacteria [31,71].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="345"> |
|
<prop type="lengthRatio">1.125</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tagħti fondi u tippromwovi attivitajiet edukattivi, taħriġ u laqgħat dwar il-kontroll tal-antibijotiċi u r-reżistenza għall-antibijotiċi għall-professjonisti tal-kura tas-saħħa kollha (tobba, speċjalisti tal-mard infettiv, spiżjara, mikrobijoloġisti u persunal tal-infermiera) [19,53,56].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Fund and promote educational activities, training, and meetings about antibiotic stewardship and antibiotic resistance for all healthcare professionals (physicians, infectious disease specialists, pharmacists, microbiologists and nursing staff) [19,53,56].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="346"> |
|
<prop type="lengthRatio">1.1487603305785123</prop> |
|
<tuv xml:lang="en"> |
|
<seg>d) Tippromwovi preskriventi u mexxejja tat-timijiet ta' kontroll tal-antibijotiċi biex jikkollaboraw u jwettqu verifika u rispons proattiv.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>d) Promoting prescribers and antibiotic stewardship team leaders to collaborate and conduct proactive audit and feedback.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="347"> |
|
<prop type="lengthRatio">1.2916666666666667</prop> |
|
<tuv xml:lang="en"> |
|
<seg>• l-użu ta' testijiet dijanjostiċi rapidi u ta' punt ta' kura.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>use of rapid and point-of-care diagnostic tests.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="348"> |
|
<prop type="lengthRatio">1.35</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Bħalissa madwar l-Ewropa diġà qegħdin jiġu organizzati għadd ta' inizjattivi sabiex jitwasslu l-messaġġi dwar ir-riskji assoċjati ma' l-użu mhux xieraq ta' l-antibijotiċi u qed tiġi mogħtija informazzjoni dwar l-użu prudenti ta'l-antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>A number of initiatives are taking place across Europe to spread the messages on the risks associated with inappropriate use of antibiotics and how to take antibiotics responsibly.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="349"> |
|
<prop type="lengthRatio">0.3157894736842105</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Kampanji fl-Ewropa</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Belgian Antibiotic Policy Coordination Committee (BAPCOC)</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="350"> |
|
<prop type="lengthRatio">2.75</prop> |
|
<tuv xml:lang="en"> |
|
<seg>INIZJATTIVA EWROPEA DWAR IS-SAĦĦA</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Infographics</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="351"> |
|
<prop type="lengthRatio">0.7567567567567568</prop> |
|
<tuv xml:lang="en"> |
|
<seg>immaġni materjal tat-toolkit</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>information material toolkit material</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="352"> |
|
<prop type="lengthRatio">0.6370967741935484</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-udjenzi sekondarji huma maniġers ta' sptarijiet u, f'livell inqas, spiżjara fi sptarijiet u kumitati għall-amministrazzjoni ta' farmaċewtiċi / antibijotiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Its objective is to provide practical support to prescribers on the considerations of antibiotic prescribing and the questions they need to ask themselves before, during and after making the decision to administer antibiotic treatments to patients.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="353"> |
|
<prop type="lengthRatio">1.146341463414634</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Messaġġi ewlenin għall-mikrobijoloġisti kliniċi</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for clinical microbiologists</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="354"> |
|
<prop type="lengthRatio">1.2574257425742574</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Messaġġi ewlenin għall-professjonisti tal-prevenzjoni u l-kontroll tal-infezzjonijiet tal-isptar u l-epidemjoloġisti tal-isptar</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for hospital infection prevention and control professionals and hospital epidemiologists</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="355"> |
|
<prop type="lengthRatio">1.1714285714285715</prop> |
|
<tuv xml:lang="en"> |
|
<seg>infografika, materjal ta' informazzjoni -</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>infographic, information material -</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="356"> |
|
<prop type="lengthRatio">1.2580645161290323</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 1 // 8 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 1 // 10 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="357"> |
|
<prop type="lengthRatio">1.4489795918367347</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Reżistenza li qed tikber għal antibijotiċi tal-aħħar ġenerazzjoni: 2013</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Growing resistance to last-line antibiotics: 2013</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="358"> |
|
<prop type="lengthRatio">0.8048780487804879</prop> |
|
<tuv xml:lang="en"> |
|
<seg>INIZJATTIVA EWROPEA DWAR IS-SAĦĦA</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>See a joint EMA/ECDC/EFSA/EEA infographic</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="359"> |
|
<prop type="lengthRatio">1.1504424778761062</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Huwa stmat li total ta' 8.9 miljun HAI iseħħ kull sena flisptarijiet u fil-faċilitajiet tal-kura fuq terminu twil Ewropej f'daqqa.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>A total of 8.9 million HAIs were estimated to occur each year in European hospitals and long-term care facilities</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="360"> |
|
<prop type="lengthRatio">1.0</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Evitaw profilassi antibijotika bla bżonn [31].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Avoid unnecessary antibiotic prophylaxis [31].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="361"> |
|
<prop type="lengthRatio">0.9166666666666666</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Pereżempju:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>For example:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="362"> |
|
<prop type="lengthRatio">1.15</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Timplimentaw strateġiji tal-prevenzjoni u l-kontroll tal-infezzjonijiet, inkluż [86,87,105]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Implementing infection prevention and control strategies, including [86,87,105]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="363"> |
|
<prop type="lengthRatio">1.0486111111111112</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-parteċipazzjoni regolari fl-attivitajiet edukattivi, kif ukoll rispons u verifiki proattivi, flimkien mat-tim tal-kontroll tal-antibijotiċi [54,56].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Participating in education activities regularly, as well as proactive audits and feedback together with the antibiotic stewardship team [54,56].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="364"> |
|
<prop type="lengthRatio">1.1644736842105263</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Iddokumentaw l-indikazzjoni tat-trattament antibijotiku, l-għażla tal-mediċina, id-doża, ir-rotta tal-amministrazzjoni u t-tul tat-trattament fiċ-ċart tal-pazjenti[31,42,70,71].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Document the indication of antibiotic treatment, drug choice, dose, route of administration and duration of treatment in the patient chart[31,42,70,71].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="365"> |
|
<prop type="lengthRatio">1.1984126984126984</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Torganizzaw rawnds tal-persunal multidixxiplinarju regolari u diskussjonijiet dwar il-każijiet biex ittejbu l-kwalità tat-trattament antibijotiku [72].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>3. Organising regular multidisciplinary staff rounds and case discussions to improve the quality of antibiotic treatment [72].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="366"> |
|
<prop type="lengthRatio">1.175531914893617</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Timplimentaw gwida (linji gwida, protokolli u listi ta' kontroll) għall-miżuri ta' prevenzjoni u kontroll tal-infezzjonijiet, flimkien mat-tim tal-prevenzjoni u l-kontroll tal-infezzjonijiet [86,87] [kunsens tal-esperti].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Implement guidance (guidelines, protocols and checklists) for infection prevention and control measures, together with the infection prevention and control team [86,87] [expert consensus].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="367"> |
|
<prop type="lengthRatio">0.65</prop> |
|
<tuv xml:lang="en"> |
|
<seg>b) Is-sett tal-interventi jista' jipprevjeni pulmonite assoċjata mal-ventilaturi fl-unitajiet tal-kura intensiva tal-adulti [108].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>a) Complying with a central-line care protocol (for insertion and maintenance), reduces central-line-associated bloodstream infections in all types of intensive care units (adults and neonatal) [107].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="368"> |
|
<prop type="lengthRatio">1.1527777777777777</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Qisu bir-reqqa l-istorja tal-pazjent meta tippreskrivu antibijotiku, inkluż l-użu tal-antibijotiku riċenti, l-allerġiji għall-mediċini, l-użu ta' terapija immunosuppressiva u fatturi tar-riskju għar-reżistenza għall-antibijotiku (pereżempju, rikoveru riċenti fl-isptar, proċedura riċenti jew vjaġġar riċenti barra mill-Ewropa) [31].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Take a thorough patient history when you prescribe an antibiotic, including recent antibiotic use, drug allergies, use of immunosuppressive therapy, and risk factors for antibiotic resistance (for example, recent hospitalisation, recent procedure or recent travel outside of Europe) [31].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="369"> |
|
<prop type="lengthRatio">1.2545454545454546</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Meta ssegwu l-miżuri tal-prevenzjoni u l-kontroll tal-infezzjonijiet, tnaqqsu l-inċidenza tal-infezzjonijiet assoċjati mal-kura tas-saħħa.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Following infection prevention and control measures reduces the incidence of healthcare-associated infections.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="370"> |
|
<prop type="lengthRatio">0.18</prop> |
|
<tuv xml:lang="en"> |
|
<seg>għas-sepsis) [90].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Following antibiotic treatment protocols, based on evidence-based guidelines (e.g. for sepsis) [90].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="371"> |
|
<prop type="lengthRatio">1.3452380952380953</prop> |
|
<tuv xml:lang="en"> |
|
<seg>It-tnaqqis u r-razzjonalizzazzjoni tat-terapija tal-antibijotiċi jwasslu għal riżultati aħjar tal-pazjenti [106].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Narrowing or streamlining antibiotic therapy leads to better patient outcomes [106].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="372"> |
|
<prop type="lengthRatio">0.5853658536585366</prop> |
|
<tuv xml:lang="en"> |
|
<seg>mikrobijoloġisti kliniċi</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for clinical microbiologists</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="373"> |
|
<prop type="lengthRatio">1.246031746031746</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Tħarrġu lill-preskriventi tal-isptar b'mod regolari dwar ir-reżistenza għall-antibijotiċi u dar it-testijiet dijagnostiċi rapidi u ta' punt ta' kura [31,53].</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Train hospital prescribers regularly on antibiotic resistance, and on use of rapid and point-of-care diagnostic tests [31,53].</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="374"> |
|
<prop type="lengthRatio">1.3488372093023255</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-kompiti tagħkom li għandhom x'jaqsmu mal-użu mtejjeb tal-antibijotiku jinkludu [31,98-100] [kunsens tal-esperti]:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Your tasks related to improving antibiotic use include [31,98-100] [expert consensus]:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="375"> |
|
<prop type="lengthRatio">1.28</prop> |
|
<tuv xml:lang="en"> |
|
<seg>j) Tiġġestixxu l-formularju antimikrobjali tal-isptar tagħkom (jiġifieri, il-lista tal-mediċini disponibbli għall-preskriventi).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>j) Managing your hospital's antimicrobial formulary (i.e., list of drugs available for prescribers).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="376"> |
|
<prop type="lengthRatio">1.2903225806451613</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Paġna 1 minn 2 // 12 Riżultati li nstabu</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Page 1 of 2 // 14 Results found</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="377"> |
|
<prop type="lengthRatio">1.4579439252336448</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-messaġġi ewlenin huma bbażati fuq artiklu ppubblikat f'The Lance Infectious Diseases fil-5 ta' Novembru 2018, Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>November 2018, Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="378"> |
|
<prop type="lengthRatio">1.146814404432133</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-artiklu jistma l-piż ta' ħames tipi ta' infezzjonijiet ikkawżati minn batterji reżistenti għall-antibijotiċi , (8 speċi ta' batterji, 16-il kombinazzjoni ta' batterja reżistenti għall-antibijotiċi) ta' tħassib dwar is-saħħa pubblika fil-pajjiżi tal-Unjoni Ewropea u taż-Żona Ekonomika Ewropea (UE/ŻEE) fl-2015, imkejjel fin-numru ta' każijiet, imwiet attribwibbli u snin ta' ħajja aġġustati b'diżabilità (DALYs).</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>The article estimates the burden of five types of infections caused by antibiotic-resistant bacteria, (8 bacteria species, 16 antibiotic resistance-bacterium combinations) of public health concern in European Union and European Economic Area (EU/EEA) countries in 2015, measured in number of cases, attributable deaths and disabilityadjusted life years (DALYs).</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="379"> |
|
<prop type="lengthRatio">1.043010752688172</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Dan huwa komparabbli man-numru totali ta' passiġġieri ta' aktar minn 100 ajruplan ta' daqs medju.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>This is comparable to the total number of passengers of more than 100 medium-sized airplanes.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="380"> |
|
<prop type="lengthRatio">1.3157894736842106</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Il-piż tas-saħħa tar-reżistenza għall-antibijotiċi</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Health burden of antibiotic resistance</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="381"> |
|
<prop type="lengthRatio">1.0810810810810811</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Bejn l-2007 u l-2015, il-piż ta' kull waħda mis-16-il batterja reżistenti għall-antibijotiċi li qed tiġi studjata żdied:</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>3. Between 2007 and 2015, the burden of each of the 16 antibiotic-resistant bacteria under study has increased:</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="382"> |
|
<prop type="lengthRatio">1.0887096774193548</prop> |
|
<tuv xml:lang="en"> |
|
<seg>39 % tal-piż huwa kkawżat mill-infezzjonijiet b'batterji reżistenti għall-antibijotiċi tal-aħħar linja bħall-karbapenemi u l-kolistina.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>39% of the burden is caused by infections with bacteria resistant to last-line antibiotics such as carbapenems and colistin.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="383"> |
|
<prop type="lengthRatio">1.2181818181818183</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Kull sena madwar l-Ewropa, l-EAAD jiġi mfakkar fit-18 ta' Novembru.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Each year across Europe, EAAD is marked on 18 November.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="384"> |
|
<prop type="lengthRatio">1.19693094629156</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-ECDC jissieħeb ukoll ma' bosta organizzazzjonijiet professjonali u tal-pazjenti, mal-Kummissjoni Ewropea, mal-Awtorità Ewropea dwar is-Sigurtà fl-Ikel, mal-Aġenzija Ewropea għall-Mediċini u mal-Uffiċċju Reġjonali tal-Organizzazzjoni Dinjija tas-Saħħa għall-Ewropa, kif ukoll ma' kampanji internazzjonali fl-Istati Uniti, fl-Awstralja, fi New Zealand, fil-Kanada u fil-Ġappun, biex iwettaq numru ta' azzjonijiet biex tiġi indirizzata r-reżistenza għall-antimikrobiċi.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>ECDC also partners with numerous professional and patient organisations, the European Commission, the European Food Safety Authority, the European Medicines Agency and the World Health Organization Regional Office for Europe, as well international campaigns in the United States, Australia, New Zealand, Canada and Japan, to undertake a number of actions to address antimicrobial resistance.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="385"> |
|
<prop type="lengthRatio">0.6753246753246753</prop> |
|
<tuv xml:lang="en"> |
|
<seg>L-oqsma ewlenin ta' ħidma tal-ECDC jinkludu s-sorveljanza, l-intelliġenza epidemika, l-iżvilupp ta' gwida bbażata fuq l-evidenza u reviżjonijiet sistematiċi, taħriġ kif ukoll appoġġ lill-Istati Membri tal-UE.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Activities related to this topic at ECDC take place under the Antimicrobial Resistance and Healthcare-associated Infections programme . ECDC's main areas of work include surveillance, epidemic intelligence, developing evidence-based guidance and systematic reviews, training, support to the EU Member States.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="386"> |
|
<prop type="lengthRatio">1.0858585858585859</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Messaġġi ewlenin għall-professjonisti tal-kura tas-saħħa fi sptarijiet u f'ambjenti oħrajn tal-kura tas-saħħa: maniġers/amministraturi, speċjalisti tal-mard infettiv, prevenzjoni tal-infezzjonijiet u professjonisti tal-kontroll, preskriventi, tobba subalterni u studenti, spiżjara, infermiera, mikrobijoloġisti kliniċi u professjonisti f'dipartimenti tal-emerġenza, fl-unitajiet tal-kura intensiva u faċilitajiet tal-kura fit-tul.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Key messages for professionals working at hospitals and other healthcare settings: managers/administrators, infectious disease specialists, infection prevention and control professionals, epidemiologists, prescribers, junior doctors and students, pharmacists, nurses, clinical microbiologists, and professionals in emergency departments, in intensive care units, and in long-term care facilities.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="387"> |
|
<prop type="lengthRatio">0.9411764705882353</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ippjana kampanja</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Join the campaign</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="388"> |
|
<prop type="lengthRatio">1.1730769230769231</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Ingħaqad magħna fuq Facebook: http://www.facebook.com/EAAD.EU</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Join us on Facebook: http://www.facebook.com/EAAD.EU</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="389"> |
|
<prop type="lengthRatio">1.1428571428571428</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Segwina fuq Twitter, tweet #EAAD jew hu sehem fiċ-‘chats' tagħna fuq twitter dwar l-EAAD: http://www.twitter.com/EAAD_EU</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Follow us on Twitter, use #EAAD or take part in our twitter chats on EAAD: http://www.twitter.com/EAAD_EU</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="390"> |
|
<prop type="lengthRatio">1.3717277486910995</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Għin fir-reklamar tal-Jum Ewropew għall-Għarfien dwar l-Antibijotiċi fi newsletters, fuq siti elettroniċi, fil-mezzi tal-komunikazzjoni tal-massa u fuq l-Internet, billi ddaħħal link fil-sit tiegħek, fil-firma tal-posta elettronika tiegħek jew fil-blogg tiegħek.</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Help advertise the European Antibiotic Awareness Day in newsletters, websites, in the media and on the Internet, by inserting a link on your website, in your e-mail signature or in your blog.</seg> |
|
</tuv> |
|
</tu> |
|
<tu tuid="391"> |
|
<prop type="lengthRatio">1.2173913043478262</prop> |
|
<tuv xml:lang="en"> |
|
<seg>Informazzjoni għall-pazjenti</seg> |
|
</tuv> |
|
<tuv xml:lang="mt"> |
|
<seg>Information to patients</seg> |
|
</tuv> |
|
</tu> |
|
</body> |
|
</tmx> |
|
|
